0001437749-23-024064.txt : 20230817 0001437749-23-024064.hdr.sgml : 20230817 20230817161557 ACCESSION NUMBER: 0001437749-23-024064 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 25 CONFORMED PERIOD OF REPORT: 20230815 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230817 DATE AS OF CHANGE: 20230817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CervoMed Inc. CENTRAL INDEX KEY: 0001053691 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300645032 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37942 FILM NUMBER: 231182116 BUSINESS ADDRESS: STREET 1: 20 PARK PLAZA STREET 2: SUITE 424 CITY: BOSTON STATE: MA ZIP: 02216 BUSINESS PHONE: (617) 744-4400 MAIL ADDRESS: STREET 1: 20 PARK PLAZA STREET 2: SUITE 424 CITY: BOSTON STATE: MA ZIP: 02216 FORMER COMPANY: FORMER CONFORMED NAME: Diffusion Pharmaceuticals Inc. DATE OF NAME CHANGE: 20160115 FORMER COMPANY: FORMER CONFORMED NAME: RestorGenex Corp DATE OF NAME CHANGE: 20140307 FORMER COMPANY: FORMER CONFORMED NAME: Stratus Media Group, Inc DATE OF NAME CHANGE: 20080722 8-K 1 dffn20230816_8k.htm FORM 8-K dffn20230816_8k.htm
false 0001053691 0001053691 2023-08-15 2023-08-15
--12-31
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
 
FORM 8-K
___________________________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
August 15, 2023
Date of Report (Date of earliest event reported)
___________________________
 
CervoMed Inc.
(Exact name of registrant as specified in its charter)
___________________________
Delaware
001-24477
30-0645032
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 
20 Park Plaza, Suite 424
Boston, Massachusetts
02216
(Address of principal executive offices)
(Zip Code)
 
Registrants telephone number, including area code: (617) 744-4400
 
Diffusion Pharmaceuticals Inc.
300 East Main Street, Suite 201
Charlottesville, Virginia 22902
(Former name or former address, if changed since last report)
___________________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.001 par value
 
CRVO
 
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


 
 

 
Explanatory Note
 
On August 16, 2023, the Delaware corporation formerly known as “Diffusion Pharmaceuticals Inc.” completed its previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of March 30, 2023 (the “Merger Agreement”), by and among Diffusion Pharmaceuticals Inc. (“Diffusion”), Dawn Merger Sub Inc., a wholly owned subsidiary of Diffusion (“Merger Sub”), and EIP Pharma, Inc. (“EIP”), pursuant to which Merger Sub merged with and into EIP, with EIP surviving the merger as a wholly owned subsidiary of Diffusion (the “Merger”). Additionally, on August 16, 2023, the Company changed its name from “Diffusion Pharmaceuticals Inc.” to “CervoMed Inc.” (the “Company”). See Item 2.01 for additional information regarding completion of the Merger.
 
Item 2.01         Completion of Acquisition or Disposition of Assets
 
As previously disclosed, on March 30, 2023, Diffusion, Merger Sub and EIP entered into the Merger Agreement. Upon the terms and subject to the satisfaction (or waiver) of the conditions described in the Merger Agreement, including the approval of the transaction by Diffusion’s stockholders, Merger Sub would be merged with and into EIP, with EIP surviving the Merger as a wholly owned subsidiary of Diffusion. The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. In connection with the Merger, certain officers, directors and stockholders of EIP and continuing directors of Diffusion entered into lock-up agreements, pursuant to which they accepted certain restrictions on transfers of the shares of the Company following the effective time of the Merger (the “Effective Time”).
 
On August 16, 2023, in connection with the transactions contemplated by the Merger Agreement and following a special meeting of Diffusion’s stockholders (the “Special Meeting”) and prior to the effective time of the Merger Certificate (as defined below), Diffusion filed a certificate of amendment to its Certificate of Incorporation, as amended (the “Diffusion Charter”) effecting a reverse stock split of Diffusion’s common stock, par value $0.001 per share (“Diffusion common stock”), at a ratio of 1-for-1.5 (the “Reverse Stock Split”) (the “Reverse Stock Split Amendment”).
 
Also on August 16, 2023, Diffusion, Merger Sub and EIP consummated the transactions contemplated by the Merger Agreement. Pursuant to the Certificate of Merger filed with the Secretary of State of the State of Delaware on August 16, 2023 (the “Merger Certificate”), Merger Sub was merged with and into EIP and EIP became a wholly owned subsidiary of the Company. At the Effective Time, each outstanding share of EIP capital stock (after giving effect to (i) the automatic conversion of all shares of EIP preferred stock into shares of EIP common stock, (ii) the conversion of EIP’s convertible notes into shares of EIP common stock, and excluding any shares held as treasury stock by EIP or held or owned by Diffusion or any subsidiary of Diffusion or EIP and any dissenting shares) was converted into the right to receive 0.1151 shares of Diffusion common stock, which resulted in the issuance by Diffusion of an aggregate of 5,674,250 shares of Diffusion common stock to the stockholders of EIP (the “Exchange Shares”). Certain former EIP equity holders received pre-funded warrants at the Effective Time in lieu of an equivalent number of shares of Diffusion common stock. The issuance of the Exchange Shares was registered with the SEC on a Registration Statement on Form S-4, as amended (Reg. No. 333-271823) (the “Registration Statement”). The shares of Diffusion common stock listed on the Nasdaq Capital Market, previously trading through the close of business on August 16, 2023 under the ticker symbol “DFFN,” commenced trading on a post-Reverse Stock Split basis on the Nasdaq Capital Market on August 17, 2023, under the ticker symbol “CRVO.” The common stock has a new CUSIP number, 15713L109. In addition, at the Effective Time, Diffusion assumed the EIP 2018 Employee, Director and Consultant Equity Incentive Plan (the “EIP Plan”) and each outstanding and unexercised option to purchase EIP common stock and each outstanding and unexercised warrant to purchase EIP capital stock were adjusted with such stock options and warrants (“Warrants”) henceforth representing the right to purchase a number of shares of the Company’s common stock equal to 0.1151 multiplied by the number of shares of EIP common stock previously represented by such options and warrants.
 
The Merger is being treated as a reverse recapitalization under U.S. generally accepted accounting principles. EIP is considered the accounting acquirer for financial reporting purposes.
 
Immediately following to the consummation of the Merger, Diffusion filed a certificate of amendment (the “Name Change Amendment”) to the Diffusion Charter changing its name from “Diffusion Pharmaceuticals Inc.” to “CervoMed Inc.”
 
Following the consummation of the Merger, the business previously conducted by EIP became the business conducted by the Company, which is now a clinical-stage biopharmaceutical company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38α). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB. The Company’s headquarters are located in Boston, Massachusetts (EIP’s former headquarters).
 
 

 
Immediately following the consummation of the Merger, there were approximately 5.7 million shares of the Company’s common stock outstanding, with prior EIP equityholders collectively owning approximately 77.95% of the Company and prior Diffusion equityholders collectively own approximately 22.05% of the Company, in each case, on a fully-diluted basis.
 
The foregoing descriptions of the Merger Agreement, the Merger Certificate, the Reverse Stock Split Amendment, the Name Change Amendment and Warrants do not constitute a complete summary of the terms of the Merger Agreement, the Merger Certificate, the Reverse Stock Split Amendment, the Name Change Amendment or the Warrants, and are qualified in their entirety by reference to the full text of the Merger Agreement, the Merger Certificate, the Reverse Stock Split Amendment, the Name Change Amendment and the form of Warrant, copies of which are attached to this Current Report on Form 8-K as Exhibits 2.1, 3.2, 3.3, 3.4 and 4.1 hereto and are incorporated herein by reference.
 
Item 3.03.         Material Modification to Rights of Security Holders.
 
To the extent required by Item 3.03 of Form 8-K, the information contained in Item 2.01 of this Current Report on Form 8-K regarding the Reverse Stock Split Amendment is incorporated by reference herein.
 
As previously disclosed, at the Special Meeting, Diffusion’s stockholders approved the Reverse Stock Split Amendment to effect the Reverse Stock Split within a range of one new share for not less than 1.5 and not greater than 8 shares outstanding and, in connection with the Special Meeting, Diffusion’s board of directors made the determination to implement the Reverse Stock Split at a ratio of one new share for every 1.5 pre-split shares.
 
On August 16, 2023, in connection with the Merger, Diffusion filed the Reverse Stock Split Amendment effecting the Reverse Stock Split. As of the opening of trading on The Nasdaq Capital Market on August 17, 2023, the Company’s common stock commenced trading on a Reverse Stock Split-adjusted basis under the ticker symbol “CRVO”.
 
As a result of the Reverse Stock Split, the number of issued and outstanding shares of Diffusion common stock immediately prior to the Reverse Stock Split was reduced into a smaller number of shares, such that every 1.5 shares of Diffusion common stock held by a stockholder immediately prior to the Reverse Stock Split were combined and reclassified into one share of Diffusion’s common stock after the Reverse Stock Split.
 
No fractional shares were issued in connection with the Reverse Stock Split. In accordance with the Reverse Stock Split Amendment, each stockholder who would otherwise be entitled to receive a fractional share of Diffusion’s common stock upon the consummation of the Reverse Stock Split shall have that fractional share rounded up to one additional whole share.
 
In accordance with the Reverse Stock Split Amendment, no corresponding adjustment was made with respect to the Company’s authorized shares of common stock or preferred stock. The Reverse Stock Split has no effect on the par value of the Company’s common stock or preferred stock. Immediately after the Reverse Stock Split and prior to the consummation of the Merger, each stockholder’s percentage ownership interest in Diffusion and proportional voting power remained unchanged, other than as a result of the rounding to eliminate fractional shares, as described in the preceding paragraph. The rights and privileges of the holders of shares of Diffusion common stock were unaffected by the Reverse Stock Split. Proportional adjustments have also been made to the Company’s outstanding warrants, stock options, and restricted stock units, as well as to the reserves available pursuant to and terms of the Company’s 2015 Equity Incentive Plan, as amended, to reflect the Reverse Stock Split, in each case, in accordance with the terms thereof.
 
The foregoing description of the Reverse Stock Split Amendment is not complete and is subject to and qualified in its entirety by reference to the Reverse Stock Split Amendment, a copy of which is attached as Exhibit 3.3 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Item 4.01         Change in Registrants Certifying Accountant.
 
(a) On August 16, 2023, the Audit Committee (the “Audit Committee”) of the board of directors of the Company approved the dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm, effective immediately.
 
The reports of KPMG on the Company’s consolidated financial statements as of and for each of the two fiscal years ended December 31, 2022 and December 31, 2021 did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.
 
 

 
During the two fiscal years ended December 31, 2022 and December 31, 2021, and the subsequent interim period through August 16, 2023, there were no: (1) “disagreements” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) between the Company and KPMG on any matter of accounting principles or practices, financial statement disclosure or auditing scope and procedures, which if not resolved to the satisfaction of KPMG, would have caused KPMG to make reference in connection with their opinion to the subject matter of the disagreement, or (2) reportable events (as defined by Item 304(a)(1)(v) of Regulation S-K).
 
The Company provided KPMG with a copy of the disclosures it is making in this Item 4.01 and requested that KPMG furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made in this Item 4.01. A copy of KPMG’s letter, dated August 17, 2023, is filed as Exhibit 16.1 to this Current Report on Form 8-K.
 
(b) On August 16, 2023, the Audit Committee approved, on behalf of the Company, the engagement of RSM US LLP (“RSM”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Prior to the completion of the Merger, RSM served as the auditor of EIP since December 2017.
 
During the years ended December 31, 2022 and 2021, and the subsequent interim period through August 16, 2023, neither Diffusion nor anyone on its behalf consulted with RSM, regarding either (i) the application of accounting principles to a specific transaction, completed or proposed, or the type of audit opinion that might be rendered on Diffusion’s financial statements, and neither a written report nor oral advice was provided to Diffusion that RSM concluded was an important factor considered by Diffusion in reaching a decision as to any accounting, auditing or financial reporting issue or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).
 
Item 5.01         Changes in Control of Registrant
 
To the extent required by Item 5.01 of Form 8-K, the disclosures contained in Items 2.01 and 5.02 of this Current Report on Form 8-K are incorporated herein by reference.
 
Immediately following the consummation of the Merger, the prior EIP equityholders collectively owned approximately 77.95% of the Company and the prior Diffusion equityholders collectively owned approximately 22.05% of the Company, in each case, on a fully-diluted basis. In addition, the seven-member board of directors of the Company includes five individuals who are designees of EIP and served as members of the board of directors of EIP immediately prior to the Merger. These directors possess majority control of the board of directors of the Company.
 
In accordance with the Merger Agreement, on August 16, 2023, immediately prior to the Effective Time, each of Alan Levin, Robert Adams, J.D., Mark T. Giles, J.D., Diana Lanchoney, M.D. and Robert J. Cobuzzi, Jr., resigned from the Company’s board of directors and any respective committees of the board of directors to which they belonged. Following such resignation, at the Effective Time, on August 16, 2023, the Company’s board of directors and its committees were reconstituted, with Sylvie Grégoire, Pharm.D., Jeff Poulton, Marwan Sabbagh, M.D., Frank Zavrl, John Alam, M.D., being appointed as directors of the Company and Jane Hollingsworth, J.D., and Jill Davidson continuing as directors of the Company, in all cases, with terms expiring at the Company’s 2023 annual meeting of stockholders, and Dr. Grégoire was appointed Chair of the Company’s board of directors.
 
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers
 
Resignation of Directors and Termination of Executive Officers
 
In accordance with the terms of the Merger Agreement, (i) each of Alan Levin, Robert Adams, J.D., Mark T. Giles, J.D. and Diana Lanchoney, M.D. resigned from Diffusion’s board of directors and any respective committee membership of Diffusion’s board of directors, effective as of the Effective Time and (ii) Robert J. Cobuzzi Jr., Ph.D., the Company’s Chief Executive Officer, resigned as the Company’s Chief Executive Officer and as a director of the Company, in each case, as of the Effective Time and was appointed as Chief Operating Officer. William Elder will step down from his role as Principal Financial Officer and will remain employed by the Company as the General Counsel and Corporate Secretary of the Company.
 
 

 
Appointment of Directors and Executive Officers
 
At the Effective Time, the Company’s board of directors (and its committees) and executive officers were reconstituted to include the following directors and executive officers:
 
Name
 
Age
 
Position
Executive Officers
       
John Alam, M.D.
 
61
 
Chief Executive Officer, President and Director (Principal Executive Officer)
William Tanner, Ph.D.
 
65
 
Chief Financial Officer (Principal Financial Officer)
Robert J. Cobuzzi, Jr., Ph.D.
 
58
 
Chief Operating Officer
Kelly Blackburn, M.H.A.
 
59
 
Senior Vice President, Clinical Development
William Elder
 
40
 
General Counsel and Corporate Secretary
         
Non-Employee Directors
       
Sylvie Grégoire, PharmD.
 
61
 
Chair of the Board of Directors
Jane Hollingsworth, J.D.
 
65
 
Director
Jeff Poulton
 
55
 
Director
Marwan Sabbagh, M.D.
 
57
 
Director
Frank Zavrl
 
58
 
Director
Jill Davidson
 
66
 
Director
 
The directors have a term expiring at the Company’s 2023 annual meeting of stockholders.
 
The members of the Audit Committee are Jeff Poulton (Chair), Frank Zavrl and Jane Hollingsworth, J.D. The members of the Compensation Committee are Frank Zavrl (Chair), Jeff Poulton and Jane Hollingsworth, J.D. The members of the Nominating and Corporate Governance Committee are Jane Hollingsworth, J.D. (Chair), Marwan Sabbagh, M.D. and Frank Zavrl.
 
Pursuant to the terms of the Merger Agreement, each of (i) John Alam, M.D., Sylvie Grégoire, PharmD., Jeff Poulton, Marwan Sabbagh, M.D., and Frank Zavrl were appointed to the board of directors of the Company as designees of EIP and (ii) Jane Hollingsworth, J.D. and Jill Davidson remained on the board of directors of the Company as designees of Diffusion. Each of the non-employee directors of the Company will be eligible to receive compensation pursuant to the Company’s non-employee director compensation policy.
 
Executive Officers
 
John Alam, MD has served as the President and Chief Executive Officer of the Company since August 2023. Dr. Alam was EIP’s co-founder and served as EIP’s President and Chief Executive Officer and as a member of EIP’s board of directors from April 2018 to August 2023.  Prior to that, Dr. Alam served as a managing member of EIP Pharma, LLC, EIP’s predecessor entity, from its inception in 2010.  From January 2011 to August 2014, Dr. Alam served as therapeutic area head for diseases of aging at Sanofi S.A. (NASDAQ: SNY), a global pharmaceutical company.  From 1997 until 2008, he held positions of increasing responsibility at Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), most recently as Chief Medical Officer and Executive Vice President, Medicines Development.  From 1991 to 1997, Dr. Alam worked at Biogen Inc. (NASDAQ: BIIB), where he led the clinical development of Avonex, a drug that treats multiple sclerosis.  From 2014 to 2022, Dr. Alam served as a member of the board of directors of the Alliance for Aging Research, a non-profit organization dedicated to promoting innovation to address the healthcare needs of older Americans. Dr. Alam received an S.B. in chemical engineering from the Massachusetts Institute of Technology and a M.D. from Northwestern University School of Medicine. Dr. Alam completed an internal medicine residency at Brigham and Women’s Hospital and a post-doctoral fellowship at Dana-Farber Cancer Institute. 
 
The Company’s board of directors believes that Dr. Alam is qualified to serve on the combined company’s board of directors due to his service as EIP’s president and chief executive officer, and his extensive knowledge of our company and significant background in pharmaceutical research and development.
 
William Tanner, Ph.D has served as the Company’s Chief Financial Officer since August 2023. He previously served as EIP’s Chief Financial Officer from September 2022 to August 2023. Dr. Tanner has been a consultant at Danforth Advisors, a financial and operational company for outsourced corporate and clinical business functions, since November 2021 and previously served as the chief financial officer of Danforth Advisors from November 2021 to April 2022. He co-founded ImmunoGenesis, Inc., an immuno-oncology company, in May 2019 and served as its Chief Financial Officer until October 2021. From November 2022 to April 2023, Dr. Tanner served as the chief financial officer of siRNAgen Therapeutics and from May 2021 to April 2023, he served as the interim chief financial officer of Synthis Therapeutics, Inc. Prior to that, Dr. Tanner was a managing director at Brookline Capital Markets from April 2019 to May 2019, an analyst at Cantor Fitzgerald & Co. from November 2016 to November 2018, and an analyst at Guggenheim Securities from May 2015 to November 2016. Dr. Tanner earned his B.S. and Ph.D. in physiology from Texas A&M University and completed post-doctoral training in Washington University School of Medicine’s Department of Cell Biology and in the Center for Immunology. He received his MBA from Washington University’s Olin Business School.
 
 

 
Robert J. Cobuzzi, Jr., Ph.D. has served as the Company’s Chief Operating Officer since August 2023. Dr. Cobuzzi previously served as the Company’s President and Chief Executive Officer from September 2020 to August 2023, and was a member of the board of directors of the Company from January 2020 until August 2023. Dr. Cobuzzi also currently serves as a Venture Partner and Chairman of the Business Development Board for Sunstone Life Science Ventures, an independent European venture capital investment firm focused on life science therapeutic innovations. Previously, Dr. Cobuzzi served as an Advisor to the Mitochondrial Disease Research Program at the Children’s Hospital of Philadelphia, an internationally recognized hospital and research center devoted to children, from January 2019 to April 2020, and as President and Chief Executive Officer of MitoCUREia, Inc., an affiliated company, from July 2019 to July 2020. From 2005 to 2018, Dr. Cobuzzi served in various roles at Endo International PLC, a specialty branded and generic pharmaceuticals manufacturer, most recently serving as President of Endo Ventures Limited. Dr. Cobuzzi received his Bachelor of Arts in Biochemistry and Art History from Colby College and his Ph.D. in Molecular and Cellular Biochemistry from Loyola University Chicago. He served as a Post-doctoral Fellow in Experimental Therapeutics at Roswell Park Cancer Institute.
 
Kelly Blackburn, M.H.A. has served as Senior Vice President, Clinical Development of the Company since August 2023. Ms. Blackburn previously served as Senior Vice President, Clinical Development of EIP from May 2018 to August 2023. Previously, Ms. Blackburn served as Vice President, Clinical Affairs of aTyr Pharma, Inc. (NASDAQ: LIFE) from July 2013 to July 2016. Ms. Blackburn served as a clinical development consultant from September 2012 to July 2013 to a number of companies, including Agios Pharmaceuticals, Promedior Inc. and aTyr Pharma. Prior to this, Ms. Blackburn was the Vice President, Clinical Development Operations at Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), a global biotechnology company, from September 2006 to September 2012 overseeing programs for Incivek, Kalydeco as well as their early development programs. From September 2002 to August 2006, Ms. Blackburn was Director of Clinical and Safety Operations for Millennium Pharmaceuticals where she was responsible for the VELCADE program which was successfully approved during her tenure. Ms. Blackburn holds a B.S. in biochemistry from University of New Hampshire, an M.H.A. from Quinnipiac College and a M.Ed. from Cambridge College.
 
William Elder has served as the Company’s General Counsel & Corporate Secretary since September 2020. Mr. Elder previously served as Diffusion’s Principal Financial Officer from June 2023 to August 2023. Prior to joining Diffusion, Mr. Elder principally served as president and chief executive officer of BillyVonElds, LLC, a season-long and daily fantasy sports company, where he managed all corporate, legal, and operational aspects of the business from April 2019 to September 2020. From July 2020 to September 2020, Mr. Elder also served as a part-time consultant to Diffusion. From 2011 to February 2019, Mr. Elder served as a corporate and securities associate for Dechert LLP, an international law firm, where Mr. Elder’s practice focused primarily on counseling public companies on securities laws and regulatory requirements, corporate governance matters, and financial transactions in the equity and debt markets. He received his J.D. from the University of Pennsylvania Law School, an M.S. in finance from Villanova University, and a B.A. in economics from Tufts University.
 
Non-Employee Directors
 
Sylvie Grégoire, Pharm.D. has served as the Company’s Chair of the board of directors since August 2023. Dr. Grégoire was EIP’s co-founder and served as EIP’s Executive Chair and as a member of EIP’s board of directors from April 2018 to August 2023.  From May 2013 to May 2019, Dr. Grégoire served as a director for Vifor Pharma AG (SIX: VIFN), a global pharmaceutical company focused on treatments for renal disease. From September 2007 to May 2013, Dr. Grégoire served as President of the Human Genetic Therapies division of Shire plc, a global biopharmaceutical company recently acquired by Takeda Pharmaceutical Company Limited.  From 2005 to 2008, she served as a director of IDM Pharma, Inc., a publicly traded biotechnology company that now operates as a subsidiary of Takeda Pharmaceuticals Company Limited, including serving as its Executive Chair from August 2006 to October 2007. From 2004 to 2005, Dr. Grégoire served as President, Chief Executive Officer and Executive Member of the board of directors of GlycoFi, Inc., a private biotechnology company now part of Merck and Co., Inc. Prior to that, Dr. Grégoire held various leadership positions at Biogen, Inc. (NASDAQ: BIIB), including Vice-President (head) of Regulatory Affairs, Vice-President (head) of Manufacturing, and as Executive Vice President of Technical Operations. Dr. Grégoire also served at Merck and Co., Inc. in the US and internationally in clinical research and regulatory affairs.  Dr. Grégoire serves on the board of directors of Novo Nordisk A/S (NYSE: NVO), a global pharmaceutical company, where she sits on the audit committee, the nomination committee and the research and development committee. Dr. Grégoire has also serves on the board of directors of Revvity Inc (NASDAQ: RVTY) (previously PerkinElmer, Inc. (NYSE: PKI)), a publicly traded company and a provider of products, services and solutions for the diagnostics, life sciences and applied markets, since February 2015. At Revvity, she also serves on the compensation and benefits committee and the nominating and corporate governance committee. In addition, Dr. Grégoire served as chair of the board of directors of Corvidia Therapeutics, Inc., from 2016 to 2020, a private company focused on treatments for cardio-renal diseases. Corvidia was sold to NovoNordisk in 2020. Dr Gregoire serves on the board of F2G Ltd, a privately held company developing treatments for severe rare mold infections since December 2021 where she is also the chair of the Commercial Committee. Dr. Grégoire received a bachelor’s degree in Pharmacy from Laval University and a doctoral degree in Pharmacy from the State University of New York at Buffalo. 
 
The Company’s board of directors believes that Dr. Grégoire is qualified to serve on the combined company’s board of directors due to her management experience in the pharmaceutical and biotechnology sector and her broad experience of service on other boards of directors.
 
 

 
Jane H. Hollingsworth, J.D. has served as a director of the Company since September 2020. Ms. Hollingsworth previously served as Chair of Diffusion’s board of directors from September 2020 to August 2023. She currently serves as the founding Managing Partner of Militia Hill Ventures, an organization that creates, builds, and invests in life sciences companies, a role she has held since 2013. While at Militia Hill, Jane co-founded and currently serves as Executive Chair of Eliksa Therapeutics, a regenerative medicine company, co-founded and served as Executive Chair of Spirovant Sciences, a gene therapy company sold to Sumitomo Dainippon Pharma, and served as Executive Chair and CEO of Immunome Inc. (NASDAQ: IMNM), a cancer immunotherapy company. Prior to founding Militia Hill, Ms. Hollingsworth co-founded and served as Chief Executive Officer of NuPathe, Inc., a neuroscience focused biopharmaceutical company. She also co-founded and served as EVP of Auxilium Pharmaceuticals, a urology and rare disease focused biopharmaceutical company. Ms. Hollingsworth also currently serves on the boards of the life science companies Afimmune Ltd. and Ribonova, and various industry and community organizations, including the University City Science Center, the Kimmel Center for the Performing Arts and Breatcancer.Org. Ms. Hollingsworth received her B.A. from Gettysburg College and her J.D. from Villanova University.
 
The Company’s board of directors believes that Ms. Hollingsworth is qualified to serve on the combined company’s board of directors due to her industry perspective and experience, including as chief executive officer and director of a publicly-traded biopharmaceutical company, as well as her depth of her other operating and senior management experience in the industry and educational background.
 
Jeff Poulton has been a member of the Company’s board of directors since August 2023. Mr. Poulton previously served on EIP’s board of directors from April 2018 to August 2023. Since July 2019, Mr. Poulton has served as Chief Financial Officer at Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a global biopharmaceutical company based in Cambridge, Massachusetts. From January 2018 to April 2019, Mr. Poulton served as chief financial officer at Indigo Agriculture, a plant microbiome company. From September 1998 to December 2017, Mr. Poulton held various roles of increasing responsibility at Shire plc, a biotechnology company, culminating in his service as chief financial officer from July 2014 to December 2017 and a member of Shire’s executive committee and board of directors from January 2015 to December 2017. During his tenure at Shire, Mr. Poulton also lead Shire’s rare disease US/APAC and LATAM commercial operations, as well as Shire’s rare disease business unit. Prior to his tenure at Shire, Mr. Poulton led corporate finance and business development initiatives in both the gas and electric utilities industry and the materials manufacturing sector, serving in financial leadership positions at Cinergy Corporation and PPG Industries, Inc. Mr. Poulton also served as a U.S. Navy Commissioned Officer aboard the USS Peoria. Mr. Poulton holds a B.A. in Economics from Duke University and an MBA in Finance from the Kelly School of Business at Indiana University.
 
The Company’s board of directors believes that Mr. Poulton is qualified to serve on the combined company’s board of directors due to his significant financial and operational experience in the life sciences industry.
 
Frank Zavrl has been a member of the Company’s board of directors since August 2023. Mr. Zavrl previously served as a member of EIP’s board of directors from April 2018 to August 2023. From September 2017 to March 2018, Mr. Zavrl served as a member of the board of directors of EIP Pharma, LLC. Prior to that, Mr. Zavrl has served on the board of directors of Puma Biotechnology, Inc. (NASDAQ: PBYI), a publicly-traded company focused on the treatment of cancer, from September 2015 to July 2020. From 2002 to 2011, Mr. Zavrl served as a Partner at Adage Capital Management, L.P., an asset management company, where Mr. Zavrl specialized in biotechnology investments. From 1999 to 2002, Mr. Zavrl served as a Portfolio Manager at Merlin BioMed Group, a healthcare investment firm. Previously, Mr. Zavrl served from 1998 to 1999 as an analyst at Scudder Kemper Investments Inc., focusing on biotechnology investments. Mr. Zavrl received a B.S. in Biochemistry from the University of California, Berkeley and an M.B.A. from the Tuck School of Business at Dartmouth College.
 
The Company’s board of directors believes that Mr. Zavrl is qualified to serve on the combined company’s board of directors due to his significant investment experience in pharmaceutical and biotechnology companies.
 
Marwan Sabbagh, M.D. has been a member of the Company’s board of directors since August 2023. Dr. Sabbagh previously served as a member of EIP’s board of directors from November 2021 to August 2023. Since October 2021, Dr. Sabbagh has served as a professor in the Department of Neurology and recently became Vice Chairman for Research at the Barrow Neurological Institute and is board certified in neurology by the American Board of Psychiatry and Neurology. He is also a fellow of the American Academy of Neurology. Previously, from May 2018 to October 2021, Dr. Sabbagh was a neurologist and director at the Cleveland Clinic Lou Ruvo Center for Brain Health. Prior to his time at the Cleveland Clinic, Dr. Sabbagh was a director and neurologist at the Banner Sun Health Research Institute from 2000 to 2015. Dr. Sabbagh served on the board of directors of Quince Therapeutics, Inc. (f/k/a/ Cortexyme, Inc.) (NASDAQ: QNCX) from March 2022 to September 2022. Dr. Sabbagh earned his medical degree from the University of Arizona College of Medicine and his undergraduate degree from the University of California Berkeley. He completed his neurology residency at Baylor College of Medicine and a geriatric neurology and dementia fellowship at the University of California San Diego School of Medicine.
 
 

 
The company’s board of directors believes that Dr. Sabbagh is qualified to serve on the combined company’s board of directors due to his expertise in neurological diseases and extensive clinical development experience.
 
Jill Davidson has served as a member of the Company’s board of directors since July 2023. Ms. Davidson currently serves as President of Fast Scripts LLC, an early-stage medical service provider to individuals recovering from opioid addiction, a position she has held since March 2021; Co-Manager of SkiProp LLC, an owner of rental properties, a position she has held since April 2015; and Manager of Davidson LLC, an owner of various businesses and rental properties, a position she has held since 1996. Previously, Ms. Davidson served as Vice President of Omnicare, Inc. (“Omnicare”), a comprehensive pharmaceutical and chronic care service provider, from 1997 to 1999, and as Chief Operating Officer of Clasen Long Term Care Pharmacy, a medical services provider, from 1989 until it was acquired by Omnicare in 1997. Ms. Davidson has also previously served as President of the Missouri-Illinois Gateway Hemophilia Association, from 2002 to 2003, and Vice President of the National Pharmacy Roundtable, from 1995 to 1996. Ms. Davidson received her B.A. in Pharmacy from the University of Kentucky, College of Pharmacy.
 
The Company’s board of directors believes that Ms. Davidson is qualified to serve on the Company’s board of directors due to her extensive experience serving as an officer of pharmaceutical companies.
 
Family Relationships
 
John Alam, M.D., and Sylvie Grégoire, Pharm.D. are husband and wife. Other than their relationship, there are no family relationships among any of the Company’s directors or executive officers. Except as described above, there are no arrangements or understandings with another person under which the Company’s directors and executive officers were or are to be selected as a director or executive officer. Additionally, no director or executive officer of the Company is involved in legal proceedings which require disclosure under Item 401 of Regulation S-K.
 
Affiliations with 5% Stockholders
 
John Alam, M.D. is the Chief Executive Officer and President and a director of the Company and is a greater than 5% stockholder.
 
Sylvie Grégoire, Pharm.D. is the Chair of the board of directors of the Company and is a greater than 5% stockholder.
 
Other than as described herein, none of the Company’s newly appointed directors or executive officers has a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
 
Convertible Notes
 
In December 2020, EIP issued convertible promissory notes, dated December 4, 2021 (the “2020 Notes”), to predominantly related party investors, for aggregate proceeds of $5,078,500. In December 2021, the Company issued convertible promissory notes, dated December 10, 2021 (the “2021 Notes,” and collectively with the 2020 Notes, the “EIP Convertible Notes”), to predominantly related party investors, for aggregate proceeds of $6,000,000.
 
John Alam, M.D., EIP’s former President and Chief Executive Officer, purchased $500,000 of the 2020 Notes; Sylvie Grégoire, the former Executive Chair of EIP, purchased $500,000 of the 2020 Notes; Frank Zavrl, a former director of EIP, together with his spouse, Paula Zavrl, purchased an aggregate of $350,000 of the 2020 Notes and $1,000,000 of the 2021 Notes; Kelly Blackburn, EIP’s former Senior Vice President, Clinical Development, purchased an aggregate of $150,000 of the 2020 Notes; and Jeff Poulton, a former director of EIP, purchased $100,000 of the 2020 Notes.
 
In April 2022, EIP entered into an amendment with the noteholders for the 2020 Notes (the “First Amendment”). In accordance with the First Amendment, the maturity of the 2020 Notes was extended from June 2022 to December 2023, the interest rate was modified so interest accrued at 5% through the original maturity of June 2022 and at 0% thereafter, the conversion discount was increased from 20% to 30%, and a conversion price limit of $3.00 was established for certain conversion scenarios. The 2021 Notes did not accrue any interest and had a maturity date of December 2023. No payments of principal or interest were due prior to maturity.
 
Subsequent to the First Amendment, the terms of the EIP Convertible Notes provided for automatic conversion upon either (i) the occurrence of a qualified financing of at least $15,000,000 in gross proceeds, in which the outstanding principal and all accrued and unpaid interest shall convert into shares of the equity financing at a conversion price equal to the lesser of 70% of the price per share or $3.00 per share; (ii) the occurrence of an initial public offering, in which the outstanding principal and all accrued and unpaid interest shall convert into common shares offered in the initial public offering at a conversion price equal to the initial public offering price; or (iii) the occurrence of special purpose acquisition company (“SPAC”) transaction or a reverse merger, in which the outstanding principal and all accrued and unpaid interest shall convert into common shares determined in connection with and at the time of the SPAC transaction, or reverse merger, at the conversion price. The terms of the EIP Convertible Notes further provided the holders an option to convert in connection with a financing transaction that is not a qualified financing in which the outstanding principal and all accrued and unpaid interest shall convert into shares of the equity financing at a conversion price equal to the lesser of 70% of the price per share or $3.00 per share for the EIP Convertible Notes.
 
 

 
The terms of the EIP Convertible Notes further provided for payment of 150% of all outstanding principal and all accrued and unpaid interest in the event of a change in control of EIP. The 2021 Notes also have the option to fully convert to common stock at a price per share equal to the conversion price in the event of a change in control.
 
In June 2023, EIP and the noteholders of the EIP Convertible Notes amended the terms and conditions of the EIP Convertible Notes (the “Second Amendment”) to, among other things, establish a fixed conversion price of $1.47 with respect to the Merger or, with respect to any reverse merger transaction other than the Merger, 70% of the price per share of EIP common stock as determined in good faith by the EIP board of directors at the time of the execution and delivery by EIP of a definitive agreement providing for a reverse merger.
 
In addition, the 2021 Notes were amended to provide that, to the extent the conversion of such notes in the Merger were to result in the holder beneficially owning more than 9.99% of the outstanding voting stock of the combined company, such holder would be granted pre-funded warrants in lieu of common stock for the conversion of any principal and accrued but unpaid interest in excess of 9.99%. The grant of pre-funded warrants pursuant to any such conversion would not, in and of itself, impact the allocation of shares of Diffusion common stock immediately following the Merger as between the former EIP stockholders and the Diffusion stockholders.
 
On July 10, 2023, AI EIPP Holdings LLC, one of the major stockholders of EIP, sold and transferred 3,424,871 and 571,439 shares of EIP’s Series B preferred stock to Joshua Boger, another major stockholder of EIP, and Frank Zavrl, respectively, for an aggregate purchase price of approximately $2.7 million. On the same date, EIP sold and issued (x) 473,303 and 78,717 shares of EIP common stock to Joshua Boger and Frank Zavrl, respectively, for an aggregate purchase price of approximately $0.8 million
 
On July 11, 2023, EIP and AI EIPP Holdings LLC entered into an amendment to the warrant to purchase EIP Common Stock, originally purchased by AI EIPP Holdings LLC in 2018. Such amendment prohibits any exercise of the warrant that would result in AI EIPP Holdings LLC owning more than 9.99% of the outstanding voting stock of the combined company. A copy of the warrant, which was assumed by the Company in connection with the closing of the Merger, is attached to this Current Report on Form 8-K as Exhibit 4.2 hereto and is incorporated herein by reference.
 
In connection with the Closing, and pursuant to the terms of the 2021 Notes, at the Effective Time the Company issued pre-funded warrants exercisable for 495,995 shares of Company common stock to Joshua Boger in lieu of common stock. The pre-funded warrants are exercisable at any time after the issuance date until exercised in full. The pre-funded warrants are exercisable at an exercise price of $0.001 per share. A copy of the form of pre-funded warrant is attached to this Current Report on Form 8-K as Exhibit 4.3 hereto and is incorporated herein by reference.
 
Employment Agreements
 
EIP previously entered into an executive employment agreement with John Alam, M.D., dated as of April 2, 2018 and an offer letter with Kelly Blackburn, M.H.A., dated as of April 29, 2019, as amended by amendment, dated as of January 29, 2019 (collectively, referred to as the “EIP Executive Agreements” and each of Dr. Alam and Ms. Blackburn are referred to as a “EIP executive officer”). Such EIP Executive Agreements remained effective following the Effective Time and are described below. The employment of each EIP executive officer is at will.
 
John Alam, M.D.
 
In April 2018, EIP entered into an employment agreement with John Alam, M.D. pursuant to which Dr. Alam serves as EIP’s President and Chief Executive Officer. Dr. Alam’s employment agreement establishes his title, his base salary, his eligibility for an annual bonus of up to 40% of his base salary, and his eligibility for benefits made available to employees generally. Dr. Alam’s employment is at will.
 
Dr. Alam is currently entitled to a base salary of $420,000, subject to an increase at the discretion of the Company's board of directors. Dr. Alam has the opportunity to earn a target annual bonus of 40 percent of his base salary. Pursuant to the employment agreement, the term of Dr. Alam’s employment commenced on April 2, 2018 and continues until immediately prior to the consummation of a qualified financing, unless earlier terminated (a) immediately upon the executive’s death, (b) by EIP upon executive’s disability or for cause, as such terms are defined in the employment agreement, in each case upon notice thereof, or by EIP for reasons other than for disability for cause, upon at least 30 days prior notice, or (c) by the executive, upon at least 30 days prior notice. The employment agreement specifies that a qualified financing occurs when EIP sells shares of its preferred stock with (i) an aggregate purchase price of not less than $20.0 million, (ii) a price per share equal to at least one and one-half times the Series B original issue price, as defined in our certificate of incorporation, and (iii) the principal purpose of raising capital.
 
 

 
Kelly Blackburn, M.H.A.
 
In April 2018, EIP entered into an offer letter of employment with Kelly Blackburn, M.H.A., pursuant to which Ms. Blackburn serves as EIP’s Vice President Clinical Development. Ms. Blackburn’s employment offer letter establishes her title, her base salary of $180,000, and her eligibility for benefits made available to employees generally. Ms. Blackburn’s employment is at will.  The terms of her employment agreement specify that Ms. Blackburn will devote approximately 60% of her business time and energies to the business affairs of EIP. In connection with her employment, in May 2018, Ms. Blackburn was granted a non-qualified stock option to purchase 72,000 shares of EIP Common Stock at a price per share of $2.28, which was the fair market value on the date of the grant and will be adjusted in accordance with the terms of the Merger Agreement described above. The option vested as to 25% of the shares on May 1, 2019 with the remainder vesting over the subsequent three years in equal monthly installments. In January 2019, EIP and Ms. Blackburn entered into an amendment to her employment offer letter, pursuant to which (a) the percentage of Ms. Blackburn’s business time and energies to be devoted to EIP was increased to 80% and (b) Ms. Blackburn’s annual base salary was increased to $240,000. Ms. Blackburn continues to be eligible to receive an annual bonus of up to 30% of her base salary. In connection with entry into the amendment to her offer letter, Ms. Blackburn was granted in March 2019 a non-qualified stock option to purchase 48,000 shares of EIP Common Stock at a price per share of $3.19, which was the fair market value on the date of the grant and will be adjusted in accordance with the terms of the Merger Agreement described above. The option vested as to 25% of the shares on January 29, 2020, with the remainder vesting over the subsequent three years in equal monthly installments.
 
The foregoing descriptions of the EIP Executive Agreements are not complete and are subject to and qualified in its entirety by reference to such agreements, copies of which are attached to this Current Report on Form 8-K as Exhibits 10.1, 10.2 and 10.3 hereto and are incorporated herein by reference.
 
Diffusion previously entered into an employment agreement with each of Robert J. Cobuzzi, Jr., Ph.D., dated as of September 8, 2020, as amended by the amendment dated March 29, 2023, and William Elder, dated as of September 23, 2020, as amended by the amendment dated March 29, 2023 (collectively, referred to as the “Diffusion Executive Agreements” and each of Dr. Cobuzzi and Mr. Elder are referred to as a “Diffusion executive officer”), which are further described below. The employment of each executive officer is at will.
 
Robert J. Cobuzzi, Jr., Ph.D.
 
Effective September 8, 2020, Diffusion entered into an employment agreement with Dr. Cobuzzi pursuant to which he serves as its President & Chief Executive Officer. The employment agreement has an indefinite term. Dr. Cobuzzi is currently entitled to an initial annual base salary of $410,000, subject to an increase at the discretion of Diffusion’s board of directors. Dr. Cobuzzi has the opportunity to earn a target annual bonus of 50 percent of his base salary. For 2022, Dr. Cobuzzi’s entire base salary was paid in cash. The employment agreement contains certain severance and change of control provisions as described in more detail under the heading “—Post-Termination Severance and Change in Control Arrangements” in the Registration Statement. The employment agreement also contains certain non-competition and non-solicitation provisions (each applicable during employment and for 24 months thereafter), as well as confidentiality and non-disparagement provisions (each applicable during employment and at all times thereafter). On March 29, 2023, Diffusion entered into an amendment to its employment agreement with Dr. Cobuzzi, pursuant to which certain provisions in the original employment agreement which permitted Diffusion to pay a portion of his base salary and/or annual cash bonus in the form of equity or equity-based compensation, as determined in the good faith discretion of Diffusion’s board of directors, were eliminated.
 
William Elder
 
Effective September 23, 2020, Diffusion entered into an employment agreement with Mr. Elder pursuant to which he serves as its General Counsel & Corporate Secretary. The employment agreement has an indefinite term. Mr. Elder is entitled to an initial annual base salary of $250,000, subject to an increase at the discretion of the Board. Mr. Elder has the opportunity to earn a target annual bonus of 30 percent of his base salary. For 2022, Mr. Elder’s entire pro-rated base salary was paid in cash. The employment agreement contains certain severance and change of control provisions as described in more detail below under the heading “—Post-Termination Severance and Change in Control Arrangements” in the Registration Statement. The employment agreement also contains certain non-competition and non-solicitation provisions (each applicable during employment and for 24 months thereafter), as well as confidentiality and non-disparagement provisions (each applicable during employment and at all times thereafter). On March 29, 2023, Diffusion entered into an amendment to its employment agreement with Mr. Elder, pursuant to which certain provisions in the original employment agreement which permitted Diffusion to pay a portion of his base salary and/or annual cash bonus in the form of equity or equity-based compensation, as determined in the good faith discretion of Diffusion’s board of directors, were eliminated.
 
The foregoing descriptions of the Diffusion Executive Agreements are not complete and are subject to and qualified in its entirety by reference to such agreements, copies of which are attached to this Current Report on Form 8-K as Exhibits 10.4, 10.5, 10.6 and 10.7 hereto and are incorporated herein by reference.
 
 

 
Equity Plans
 
EIP 2018 Employee, Director and Consultant Equity Incentive Plan
 
Pursuant to the terms of the Merger Agreement, at the Effective Time, the Company assumed the EIP Plan and all of the stock options issued and outstanding under the EIP Plan. From and after the Effective Time, each outstanding EIP stock option assumed by the Company may be exercised solely for a number of shares of the Company’s common stock as determined by multiplying (i) the number of shares of EIP capital stock that were subject to such EIP stock option, as in effect immediately prior to the Effective Time, by (ii) 0.1151, the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of the Company’s common stock, at a per share exercise price determined by dividing (A) the per share exercise price of EIP capital stock subject to such EIP stock option, as in effect immediately prior to the Effective Time, by (B) 0.1151, the exchange ratio, and rounding the resulting exercise price up to the nearest whole cent. Any restriction on the exercise of any EIP stock option assumed by the Company will continue in full force and effect and the term, exercisability, vesting schedule, accelerated vesting provisions, and any other provisions of such EIP stock option will otherwise remain unchanged; provided, however, that the Company’s board of directors or a committee thereof will succeed to the authority and responsibility of EIP’s board of directors or any committee thereof with respect to each EIP stock option assumed by the Company.
 
Pursuant to the terms of the Merger Agreement, the Company is obligated to file a registration statement on Form S-8 to register the shares of the Company’s common stock issuable upon exercise of such EIP stock options promptly, but no later than 30 days following the Effective Time.
 
The foregoing description of the EIP Plan does not purport to be complete and is qualified in its entirety by reference to the text of the EIP Plan and form of stock option agreement, copies of which are attached to this Current Report on Form 8-K as Exhibit 10.8 hereto and are incorporated herein by reference.
 
Agreements with Directors and Officers
 
Indemnification Agreements
 
The Company has entered into indemnification agreements with certain of its directors and executive officers. The indemnification agreements will require the Company to indemnify these individuals to the fullest extent not prohibited by Delaware law. The foregoing description of the indemnification agreements does not purport to be complete and is qualified in its entirety by reference to the text of the form of indemnification agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.9.
 
Item 5.03         Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
 
To the extent required by Item 5.03 of Form 8-K, the information contained in Item 2.01 of this Current Report on Form 8-K and the information contained in Item 3.03 of this Current Report on Form 8-K with respect to the Reverse Stock Split and the Reverse Stock Split Amendment of this Current Report on Form 8-K is incorporated by reference herein.
 
At the Effective Time, on August 16, 2023, Diffusion filed the Name Change Amendment changing its name from “Diffusion Pharmaceuticals Inc.” to “CervoMed Inc.” The foregoing description of the Name Change Amendment is not complete and is subject to and qualified in its entirety by reference to such Name Change Amendment, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.4 hereto and is incorporated herein by reference.
 
Following the Effective Time, on August 16, 2023, the Company amended its bylaws to change the name of the Company such that all references to “Diffusion Pharmaceuticals Inc.” set forth therein were replaced with “CervoMed Inc.” (the “Bylaws Amendment”). The foregoing description of the Bylaws Amendment is not complete and is subject to and qualified in its entirety by reference to such Bylaws Amendment, a copy of which is attached to this Current Report on Form 8-K as Exhibit 3.5 hereto and is incorporated herein by reference.
 
 

 
Item 5.07         Submission of Matters to a Vote of Security Holders.
 
On August 15, 2023, Diffusion held the Special Meeting of stockholders to consider three proposals concerning matters related to Diffusion’s previously announced Merger with EIP, pursuant to the Merger Agreement. Each of Diffusion’s proposals was approved by the requisite vote of Diffusion’s stockholders as described below.
 
At the close of business on July 10, 2023, the record date for the Special Meeting, there were 2,040,287 shares of Diffusion common stock issued and outstanding. The holders of a total of 1,172,199 shares of Diffusion common stock were represented at the Special Meeting by proxy or by attendance at the virtual meeting, representing approximately 57.5% of issued and outstanding Diffusion common stock as of the record date, which total constituted a quorum for the Special Meeting in accordance with Diffusion’s bylaws.
 
The final voting results for each of the proposals voted upon at the Special Meeting are set forth below. Brokers had discretionary authority to vote for Proposals No. 2 and 3 for the shares of the Diffusion common stock held in street name, and as a result, no broker non-votes were received for Proposals No. 2 or 3. For more information on the proposals voted upon at the meeting, please refer to the Registration Statement, which was originally filed with the Securities and Exchange Commission on July 12, 2023 and declared effective by the Securities and Exchange Commission on July 13, 2023.
 
Proposal 1. To approve the issuance of shares of Diffusion capital stock pursuant to the Merger, which will represent more than 20% of the shares of Diffusion common stock outstanding immediately prior to the Merger and result in a change of control of Diffusion, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b):
 
521,953 For
203,636 Against
6,303 Abstain
440,307 Broker Non-Votes
 
Proposal 2. To approve an amendment to the certificate of incorporation, as amended, of Diffusion to effect a reverse stock split of Diffusion common stock at a ratio within the range between 1.5-for-1 to 8-for-1:
 
859,259 For
305,881 Against
7,059 Abstain
0 Broker Non-Votes
 
Proposal 3. To approve a postponement or adjournment of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposals set forth above:
 
779,597 For
323,300 Against
8,892 Abstain
0 Broker Non-Votes
 
Item 7.01         Regulation FD Disclosures.
 
On August 15, 2023, Diffusion issued a press release announcing preliminary results from the Special Meeting and the anticipated completion of the reverse stock split. The press release contains statements intended as “forward-looking statements” which are subject to the cautionary statements about forward-looking statements set forth therein. A copy of Diffusion’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
The information contained in this Item 7.01 and the accompanying exhibit is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 18. Furthermore, the information contained in this Item 7.01 and the accompanying exhibit shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.
 
Item 8.01.         Other Events
 
On August 16, 2023, the Company issued a press release announcing the closing of the Merger. The press release contains statements intended as “forward-looking statements” which are subject to the cautionary statements about forward-looking statements set forth therein. The press release is attached to this Current Report on Form 8-K as Exhibit 99.2.
 
 

 
Forward-Looking Statements
 
This Current Report on Form 8-K includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey uncertainty of future events or outcomes may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the parties’ control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, changes in the competitive and highly regulated industries in which the Company operates; variations in operating performance across competitors; changes in laws and regulations affecting the Company’s business; the ability to implement business plans, forecasts, and other expectations after the completion of the transaction; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, the Registration Statement, and the Company’s other filings with the SEC. Any forward-looking statements in this Current Report on Form 8-K speak only as of the date hereof (or such earlier date as may be identified). New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks, as well as other risks associated with the Merger, will be more fully discussed in future SEC filings and, except as required by applicable law, rule, or regulation, the Company does not undertake any obligation to update any such statements after the date of this Current Report on Form 8-K.
 
Item 9.01         Financial Statements and Exhibits
 
(a)
Financial Statements of Business Acquired
 
The financial statements of EIP Pharma for (i) the year ended December 31, 2022 were previously filed with the SEC as part of the Proxy Statement/Prospectus/Information Statement on June 23, 2023, and (ii) for the three and six months ended June 30, 2023 were filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 9, 2023, and pursuant to General Instruction B.3 of Form 8-K, are not required to be filed herewith.
 
(b)
Pro Forma Financial Information
 
The unaudited pro forma condensed consolidated financial statements of the Company and EIP Pharma for the year ended December 31, 2023 and the three and six months ended June 30, 2023 were previously filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 9, 2023, and pursuant to General Instruction B.3 of Form 8-K, are not required to be filed herewith.
 
(d)
Exhibits
 
Exhibit No.
 
Description
     
2.1¥
 
3.1
 
3.2
 
3.3
 
3.4
 
3.5
 
4.1
 
4.2
 
4.3
 
10.1+
 
10.2+
 
10.3+
 
 
 

 
Exhibit No.
 
Description
10.4+
 
10.5+
 
10.6+
 
10.7+
 
10.8+
 
10.9+
 
10.10†
 
10.11†
 
10.12†
 
16.1
 
99.1
 
99.2
 
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
¥
Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.
 
+
Indicates management contract or compensatory plan.
 
Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 17, 2023
CervoMed Inc.
By:
/s/ William Tanner, Ph.D.
Name: 
William Tanner, Ph.D.
Title: 
Chief Financial Officer
 
 
 
 
 
EX-3.2 2 ex_561997.htm EXHIBIT 3.2 ex_561997.htm

Exhibit 3.2

 

CERTIFICATE OF MERGER
OF
DAWN MERGER SUB INC.
(a Delaware corporation)
WITH AND INTO
EIP PHARMA, INC.
(a Delaware corporation)

 

Pursuant to Title 8, Section 251(c) of the General Corporation Law of the State of Delaware (the “DGCL”), the undersigned corporation, organized and existing under and by virtue of the DGCL, does hereby certify as follows:

 

FIRST: The name and state of incorporation of each of the constituent corporations are as follows:

 

Name

State of Incorporation

Dawn Merger Sub Inc.

Delaware

EIP Pharma, Inc.

Delaware

 

SECOND: That certain Agreement and Plan of Merger, dated as of March 30, 2023 (the “Merger Agreement”), by and among Diffusion Pharmaceuticals Inc., a Delaware corporation, Dawn Merger Sub Inc., a Delaware corporation, and EIP Pharma, Inc., a Delaware corporation, has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations in accordance with Section 251 and Section 228 of the DGCL.

 

THIRD: The name of the surviving corporation is EIP Pharma, Inc., a Delaware corporation (the “Surviving Corporation”).

 

FOURTH: The certificate of incorporation of the Surviving Corporation shall be amended and restated as of the effective time of the merger to read in its entirety as set forth on Exhibit A attached hereto and incorporated herein by reference, and as so amended and restated shall constitute the certificate of incorporation of the Surviving Corporation and shall continue in full force and effect until it is further amended in accordance with the terms thereof and the DGCL.

 

FIFTH: The merger shall become effective upon the filing of this Certificate of Merger with the Secretary of State of the State of Delaware.

 

SIXTH: That an executed copy of the Merger Agreement is on file at the principal place of business of the Surviving Corporation at 20 Park Plaza, Suite 424, Boston, Massachusetts 02116.

 

SEVENTH: A copy of the Merger Agreement will be furnished by the Surviving Corporation, on request and without cost, to any stockholder of either constituent corporation.

 

 

[SIGNATURE PAGE FOLLOWS]

 

 

 

The Surviving Corporation has caused this Certificate of Merger to be executed in its corporate name on August 16, 2023.

 

 

 

EIP PHARMA, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ John Alam

 

 

Name:

John Alam

 

 

Title:

President and Secretary

 

 

[Signature Page to Certificate of Merger]


 

 

Exhibit A

 

See attached.

 

 

 

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

 

OF

 

EIP PHARMA, INC.

 

1.         Name. The name of the corporation is “EIP Pharma, Inc.” (the “Corporation”).

 

2.         Registered Office and Agent. The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, Wilmington, New Castle County, DE 19801. The name of the Corporation’s registered agent at such address is The Corporation Trust Company.

 

3.         Purpose. The purposes for which the Corporation is formed are to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the “DGCL”) and to possess and exercise all of the powers and privileges granted by such law and any other law of Delaware.

 

4.         Authorized Capital. The total number of shares of common stock that the Corporation shall have authority to issue is One Hundred (100) shares, all of which are of one class and are designated as Common Stock and each of which has a par value $0.00001.

 

5.         Bylaws. The board of directors of the Corporation is authorized to adopt, amend or repeal the bylaws of the Corporation, except as otherwise specifically provided therein.

 

6.         Elections of Directors. Elections of directors need not be by written ballot unless the bylaws of the Corporation shall so provide.

 

7.         Right to Amend. The Corporation reserves the right to amend any provision contained in this Certificate as the same may from time to time be in effect in the manner now or hereafter prescribed by law, and all rights conferred on stockholders or others hereunder are subject to such reservation.

 

8.         Limitation on Liability. The Corporation is authorized to indemnify, and to advance expenses to, each current, former or prospective director, officer, employee or agent of the Corporation to the fullest extent permitted by Section 145 of the DGCL. To the fullest extent permitted by the laws of the State of Delaware, no director or officer shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. No amendment to, or modification or repeal of, this Section 9 shall adversely affect any right or protection of a director or of any officer, employee or agent of the Corporation existing hereunder with respect to any act or omission occurring prior to such amendment, modification or repeal.

 

9.         Business Combinations with Interested Stockholders. The Corporation elects not to be governed by Section 203 of the DGCL.

 

 
EX-3.3 3 ex_561998.htm EXHIBIT 3.3 ex_561998.htm

Exhibit 3.3

 

CERTIFICATE OF AMENDMENT
OF THE
CERTIFICATE OF INCORPORATION (AS AMENDED)
OF
DIFFUSION PHARMACEUTICALS INC.

 

DIFFUSION PHARMACEUTICALS INC., a corporation incorporated and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”) does hereby certify:

 

FIRST: That, at a meeting of the Board of Directors of the Corporation (the “Board of Directors”) on March 29, 2023 a resolution was duly adopted setting forth a proposed amendment to the Certificate of Incorporation (as amended) of the Corporation in the form set forth below (the “Amendment”), declaring said Amendment to be advisable and calling for consideration of said proposed Amendment by the stockholders of the Corporation.

 

“RESOLVED, that the Certificate of Incorporation (as amended) of the Corporation shall be amended by adding at the end of subsection A of Article IV thereof the following: ‘Effective upon the effective time of this Certificate of Amendment of the Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Effective Time”), each one and a half (1.5) shares of Common Stock issued and outstanding immediately prior to the Effective Time shall, automatically and without the necessity of any further action, be changed, reclassified and combined into one (1) share of Common Stock (the “Reverse Stock Split”). No fractional shares shall be issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares of Common Stock shall have that rounded up to one additional whole share. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (“Old Certificates”), shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional shares as described above.’”

 

SECOND: That, thereafter, pursuant to the resolution of the Board of Directors, the proposed Amendment was approved by the stockholders of the Corporation at the special meeting of stockholders on August 15, 2023.

 

THIRD: That the Amendment was duly adopted in accordance with the provisions of Sections 242 of the General Corporation Law of the State of Delaware.

 

 

IN WITNESS WHEREOF, the Corporation has caused this Amendment to the Certificate of Incorporation of the Corporation (as amended) to be executed by Robert J. Cobuzzi, Jr., Ph.D., its President and Chief Executive Officer, on this 16th day of August, 2023.

 

 

 

DIFFUSION PHARMACEUTICALS INC.

 

By: /s/ Robert J. Cobuzzi, Jr., Ph.D.

Name: Robert J. Cobuzzi, Jr., Ph.D.

Title: President and Chief Executive Officer

 

 
EX-3.4 4 ex_561999.htm EXHIBIT 3.4 ex_561999.htm

Exhibit 3.4

 

CERTIFICATE OF AMENDMENT

OF THE

CERTIFICATE OF INCORPORATION (AS AMENDED)

OF

DIFFUSION PHARMACEUTICALS INC.

 

Diffusion Pharmaceuticals Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”),

 

DOES HEREBY CERTIFY THAT:

 

FIRST: That, on August 8, 2023, the Board of Directors of the Corporation (the “Board”) declared advisable and approved the following amendment to the Certificate of Incorporation, as amended:

 

WHEREAS, Sections 242(a)(1) and 242(b)(1) of the General Corporation Law of the State of Delaware provide that the board of directors of a corporation may amend its certificate of incorporation after receipt of payment for its capital stock to change its corporate name without submitting such amendment to a vote of its stockholders; and

 

WHEREAS, the Board previously determined that it was advisable and in the best interests of the Corporation and its stockholders to amend the Corporation’s Certificate of Incorporation, as amended, at the effective time of the merger of Dawn Merger Sub Inc. with and into EIP Pharma, Inc. (the “Effective Time”), to change the name of the Corporation from “Diffusion Pharmaceuticals Inc.” to “CervoMed Inc.” (the “Corporate Name Change”).

 

NOW, THEREFORE, BE IT, RESOLVED, that, at the Effective Time, ARTICLE I – NAME of the Certificate of Incorporation, as amended, shall be deleted and replaced in its entirety with the following:

 

“The name of the corporation is CervoMed Inc. (the “Corporation”).”

 

RESOLVED, that the Board hereby approves the Amendment to the Certificate of Incorporation, as amended, to be filed with the Secretary of State of the State of Delaware at the Effective Time; and further

 

RESOLVED, that, at the Effective Time, the Chief Executive Officer, the Chief Financial Officer and the General Counsel (collectively, the “Authorized Officers”) be, and each of them individually hereby is, authorized, empowered and directed, on behalf of the Corporation and in its name, to file the Certificate of Amendment to the Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware, and to take all other actions necessary or appropriate, to effect the Corporate Name Change.

 

SECOND: That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Sections 242(a)(1) and 242(b)(1) of the General Corporation Law of the State of Delaware without a meeting or vote of the Corporation’s stockholders.

 

THIRD: That this Certificate of Amendment to the Certificate of Incorporation, as amended, shall be effective upon filing.

 

 

 

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment as of the 16th day of August, 2023.

 

 

 

DIFFUSION PHARMACEUTICALS INC.

   
   
 

By: /s/ William Elder

 

Name: William Elder

 

Title: General Counsel and Secretary

   
   

 

 

 
EX-3.5 5 ex_562000.htm EXHIBIT 3.5 ex_562000.htm

EXHIBIT 3.5

 

BYLAWS

OF

CERVOMED INC.

(AS AMENDED)

 

ARTICLE I
OFFICES

 

1.1     Registered Office. The address of the registered office of CervoMed Inc. (the “Corporation”) in the State of Delaware shall be 615 South Dupont Hwy., Dover, Kent County, Delaware 19901. The name of the registered agent of the Corporation at that address is National Corporate Research, Ltd.

 

1.2     Other Offices. The Corporation may have other offices, both within and without the State of Delaware, as the Board of Directors of the Corporation (the “Board of Directors”), from time to time shall determine or the business of the Corporation may require.

 

ARTICLE II

STOCKHOLDERS MEETINGS

 

2.1     Place of Meetings. Meetings of the stockholders of the Corporation may be held at any place, either within or without the State of Delaware, as may be determined from time to time by the Board of Directors. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders hall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the General Corporation Law of the State of Delaware (as amended from time to time, the “DGCL”). In the absence of any such designation or determination, meetings of the stockholders of the Corporation shall be held at the Corporation’s principal executive office.

 

2.2     Annual Meetings.

 

(a)     The annual meeting of the stockholders of the Corporation, for the purpose of election of directors and for such other business as may lawfully come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors. Nominations of persons for election to the Board of Directors of the Corporation and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders: (i) pursuant to the Corporation’s notice with respect to such meeting; (ii) by or at the direction of the Board of Directors; or (iii) by any stockholder of the Corporation who was a stockholder of record at the time of giving the stockholder’s notice provided for in the following subsection (b), who is entitled to vote at the meeting and who complied with the notice procedures set forth below in this Section 2.2.

 

(b)     At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to Section 2.2(a)(iii) above, (i) the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation, (ii) such other business must be a proper matter for stockholder action under the DGCL, and (iii) if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, has provided the Corporation with a Solicitation Notice (as defined below in Section 2.2(d)(iii)(C)(2)), such stockholder or beneficial owner must, in the case of a proposal, have delivered a proxy statement and form of proxy to holders of at least the percentage of the Corporation’s voting shares required under applicable law or the Corporation’s Certificate of Incorporation (as the same may be amended and/or restated from time to time, the “Certificate of Incorporation”) or these Bylaws (as the same may be amended and/or restated from time to time, the “Bylaws”) to carry any such proposal, or, in the case of a nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the Corporation’s voting shares reasonably believed by such stockholder or beneficial owner to be sufficient to elect the nominee or nominees proposed to be nominated by such stockholder, and must, in either case, have included in such materials the Solicitation Notice.

 

 

 

(c)     To be timely, a stockholder’s notice shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the ninetieth (90th) day, nor earlier than the close of business on the one hundred twentieth (120th) day, prior to the first anniversary of the date of the proxy statement delivered to stockholders in connection with the preceding year’s annual meeting; provided, however, that in the event (i) the date of the annual meeting is advanced more than thirty (30) days prior to or delayed by more than thirty (30) days after the anniversary of the preceding year’s annual meeting, (ii) no proxy statement was delivered to stockholders in connection with the preceding year’s annual meeting, or (iii) the Corporation did not hold an annual meeting in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the ninetieth (90th) day prior to such annual meeting and not later than the close of business on the later of the sixtieth (60th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made. In no event shall the public announcement of an adjournment of an annual meeting commence a new time period for the giving of a stockholder’s notice as described above.

 

(d)     Such stockholder’s notice shall set forth:

 

(i)     as to each person whom the stockholder proposes to nominate for election or reelection as a director, all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (as amended from time to time, the “1934 Act”) (including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected);

 

(ii)     as to any other business that the stockholder proposes to bring before the meeting, a brief description of the

business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made; and

 

(iii)     as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made:

 

(A)     the name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner;

 

(B)     (1) the class and number of shares of the Corporation which are owned beneficially and of record by such stockholder and such beneficial owner; (2) any option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from the value of any class or series of shares of the Corporation, whether such instrument or right shall be subject to settlement in the underlying class or series of capital stock of the Corporation or otherwise (a “Derivative Instrument”) directly or indirectly owned beneficially by such stockholder and such beneficial owner and any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares of the Corporation; (3) any proxy, contract, arrangement, understanding, or relationship pursuant to which such stockholder has a right to vote any shares of any security of the Corporation; (4) any short interest in any security of the Corporation (for purposes of this Bylaw a person shall be deemed to have a short interest in a security if such person directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value of the subject security) held directly or indirectly by such stockholder and such beneficial owner; (5) any rights to dividends on the shares of the Corporation owned beneficially and of record by such stockholder and such beneficial owner that are separated or separable from the underlying shares of the Corporation; (6) any proportionate interest in shares of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such stockholder or such beneficial owner is a general partner or, directly or indirectly, beneficially owns an interest in a general partner; and (7) any performance-related fees (other than an asset-based fee) that such stockholder or such beneficial owner is entitled to based on any increase or decrease in the value of shares of the Corporation or Derivative Instruments, if any, as of the date of such notice, in each case including without limitation any such interests held by members of such stockholder’s or such beneficial owner’s immediate family sharing the same household (which information shall be supplemented by such stockholder and beneficial owner, if any, not later than ten (10) days after the record date for the meeting to disclose such ownership as of the record date);

 

 

 

(C)     any other information relating to such stockholder and beneficial owner, if any, that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in a contested election pursuant to Section 14 of the 1934 Act and the rules and regulations promulgated thereunder, including without limitation:

 

(1)     a description of all arrangements or understandings between the stockholder or beneficial owner and each proposed nominee and any other person or persons (including their names) pursuant to which the nomination(s) are to be made by such stockholder; and

 

(2)     whether either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in the case of the proposal, at least the percentage of the Corporation’s voting shares required under applicable law or the Certificate of Incorporation or these Bylaws to carry the proposal or, in the case of a nomination or nominations, a sufficient number of holders of the Corporation’s voting shares to elect such nominee or nominees (an affirmative statement of such intent, a “Solicitation Notice”).

 

(e)     Notwithstanding anything in Section 2.2(c) of these Bylaws to the contrary, in the event that the number of directors to be elected to the Board of Directors of the Corporation is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the Corporation at least seventy (70) days prior to the first anniversary of the preceding year’s annual meeting (or, if the annual meeting is held more than thirty (30) days before or thirty (30) days after such anniversary date, at least seventy (70) days prior to such annual meeting) a stockholder’s notice required by this Section 2.2 shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the tenth (10th) day following the day on which such public announcement is first made by the Corporation.

 

(f)     Only such persons who are nominated in accordance with the procedures set forth in this Section 2.2 shall be eligible to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 2.2. Except as otherwise provided by law, the chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made, or proposed, as the case may be, in accordance with the procedures set forth in these Bylaws and, if any proposed nomination or business is not in compliance with these Bylaws, to declare that such defective proposal or nomination shall not be presented for stockholder action at the meeting and shall be disregarded.

 

(g)     Notwithstanding the foregoing provisions of this Section 2.2, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholders’ meeting, stockholders must provide notice as required by the regulations promulgated under the 1934 Act. Nothing in these Bylaws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy statement pursuant to Rule 14a-8 under the 1934 Act.

 

 

 

(h)     For purposes of these Bylaws, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press, PR Newswire, Reuters or comparable national news service or in a document publicly filed by the Corporation with the U.S. Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the 1934 Act.

 

2.3     Special Meetings.

 

(a)     Unless otherwise provided in the Certificate of Incorporation, special meetings of the stockholders of the Corporation may be called, for any purpose or purposes, only by (i) the Chairman of the Board of Directors, (ii) the Chief Executive Officer, or (iii) the Board of Directors pursuant to a resolution adopted by a majority of the directors then in office, and shall be held at such place, on such date and at such time as determined by the Board of Directors.

 

(b)     If a special meeting is properly called by any person or persons other than the Board of Directors, the request shall be in writing, specifying the general nature of the business proposed to be transacted, and shall be delivered personally or sent by certified or registered mail, return receipt requested, to the Secretary of the Corporation. No business may be transacted at such special meeting otherwise than specified in such notice. The Board of Directors shall determine the time and place of such special meeting, which shall be held not less than thirty-five (35) nor more than one hundred twenty (120) days after the date of the receipt of the request. Upon determination of the time and place of the meeting, the Secretary shall cause notice to be given to the stockholders entitled to vote, in accordance with the provisions of Section 2.4 of these Bylaws. Nothing contained in this subsection (b) shall be construed as limiting, fixing or affecting the time when a meeting of stockholders called by action of the Board of Directors may be held.

 

(c)     Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation’s notice of meeting (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the Corporation who is a stockholder of record at the time of giving notice provided for in these Bylaws who shall be entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 2.3(c). In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board of Directors, any such stockholder may nominate a person or persons (as the case may be), for election to such position(s) as specified in the Corporation’s notice of meeting, if the stockholder’s notice otherwise required by Section 2.2 of these Bylaws shall be delivered to the Secretary at the principal executive offices of the Corporation not earlier than the close of business on the one hundred twentieth (120th) day prior to such special meeting and not later than the close of business on the later of the ninetieth (90th) day prior to such meeting or the tenth (10th) day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board of Directors to be elected at such meeting. In no event shall the public announcement of an adjournment of a special meeting commence a new time period for the giving of a stockholder’s notice as described above.

 

(d)     Unless the Certificate of Incorporation provides otherwise, any special meeting of the stockholders may be cancelled by resolution duly adopted by a majority of the directors then in office upon public notice given prior to the date previously scheduled for such meeting of stockholders.

 

2.4     Notice of Meetings. Except as otherwise provided by law, notice, given in writing or by electronic transmission, of each meeting of stockholders shall be given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting. Such notice shall specify the place, date and hour of the meeting, the means of remote communication(s), if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting (as authorized by the Board of Directors in its sole discretion pursuant to Section 211(a)(2) of the DGCL), the record date for determining the stockholders entitled to vote at the meeting if such date is different from the record date for determining stockholders entitled to notice of the meeting, and, in the case of a special meeting, the purpose or purposes of the meeting. Notice of any meeting of stockholders, if mailed, is given when deposited in the United States mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the Corporation and otherwise is given when delivered. Notice of the time, place, and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, or by electronic transmission by such person, either before or after such meeting, and will be waived by any stockholder by his or her attendance thereat in person or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given. Neither the business to be transacted at, nor the purpose of, any annual or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by electronic transmission.

 

 

 

2.5     Determination of Stockholders of Record.

 

(a)     In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote at the adjourned meeting.

 

(b)     In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which date shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. If no record date has been fixed by the Board of Directors, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is required by the DGCL, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation’s registered office shall be by hand or by certified or registered mail, return receipt requested. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by the DGCL, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.

 

2.6     Quorum. At all meetings of the stockholders, except where otherwise provided by law, the Certificate of Incorporation or these Bylaws, the presence, in person or by proxy duly authorized, of the holders of 33.4% of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Where a separate vote by a class or series or classes or series is required, except where otherwise provided by law or by the Certificate of Incorporation or these Bylaws, 33.4% the outstanding shares of such class or series or classes or series, present in person or represented by proxy duly authorized, shall constitute a quorum entitled to take action with respect to that vote on that matter.

 

 

 

2.7     Adjournment and Notice of Adjourned Meetings. Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares present in person or represented by proxy at the meeting. When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place thereof, and the means of remote communication(s), if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting (as authorized by the Board of Directors in its sole discretion pursuant to Section 211(a)(2) of the DGCL), are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date for stockholders entitled to vote is fixed for the adjourned meeting, the Board of Directors shall fix a new record date for notice of such adjourned meeting, and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting.

 

2.8     Voting. Except as otherwise provided by law or by the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the affirmative vote of the majority of shares present in person or represented by proxy at the meeting and entitled to vote generally on the subject matter shall be the act of the stockholders. Except as otherwise provided by law, the Certificate of Incorporation or these Bylaws, directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote generally on the election of directors. Where a separate vote by a class or series or classes or series is required, except where otherwise provided by law or by the Certificate of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of shares of such class or series or classes or series present in person or represented by proxy at the meeting shall be the act of such class or series or classes or series.

 

2.9     Voting Rights. For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the Corporation on the record date, as provided in Section 6.5 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in person or by an agent or agents authorized by a proxy granted in accordance with the DGCL. An agent so appointed need not be a stockholder. No proxy shall be voted after three (3) years from its date of creation unless the proxy provides for a longer period.

 

2.10     Joint Owners of Stock. If shares or other securities having voting power stand of record in the names of two (2) or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two (2) or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect: (a) if only one (1) votes, his or her act binds all; (b) if more than one (1) votes, the act of the majority so voting binds all; (c) if more than one (1) votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Delaware Court of Chancery for relief as provided in Section 217(b) of the DGCL. If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of clauses (b) and (c) shall be a majority or even-split in interest.

 

2.11     List of Stockholders. The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting (provided, however, that if the record date for determining the stockholders entitled to vote is less than ten (10) days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth (10 ) day before the meeting date), arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Nothing contained in this Section 2.11 shall require the Corporation to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least ten (10) days prior to the meeting, (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b) during ordinary business hours, at the principal place of business of the Corporation. In the event the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then a list of stockholders entitled to vote at the meeting shall be produced and kept at the time and place of the meeting during the whole time thereof and may be examined by any stockholder of the Corporation who is present. If the meeting is to be held solely by means of remote communication, then such list shall also be open to the examination of any stockholder of the Corporation during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting.

 

 

 

2.12     Action Without Meeting.

 

(a)     Any action to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action to be so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered (by hand or by certified or registered mail, return receipt requested) to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of the stockholders are recorded.

 

(b)     Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within sixty (60) days of the earliest dated consent delivered in the manner required by this Section 2.11, written consents signed by a sufficient number of holders to take action are delivered to the Corporation as aforesaid. Delivery made to the Corporation’s registered office shall be by hand or by certified or registered mail, return receipt requested. Any person executing a consent may provide, whether through instruction to an agent or otherwise, that such a consent will be effective at a future time (including a time determined upon the happening of an event), no later than 60 days after such instruction is given or such provision is made, and, if evidence of such instruction or provision is provided to the Corporation, such later effective time shall serve as the date of signature. Unless otherwise provided, any such consent shall be revocable prior to its becoming effective.

 

(c)     Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing.

 

(d)     Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall, to the extent required by applicable law, be given to those stockholders who have not consented in writing, and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the Corporation.

 

2.13     Organization.

 

(a)     At every meeting of stockholders, (i) the Chairman of the Board of Directors or, if a Chairman of the Board of Directors has not been appointed or is absent, (ii) the Vice Chairman of the Board of Directors, if any, or, if the Vice Chairman of the Board of Directors is absent or there is no Vice Chairman of the Board of Directors, (iii) the Chief Executive Officer or, if the Chief Executive Officer is absent, (iv) such person as the Chairman of the Board of Directors shall appoint or, if such Chairman has not been appointed, (v) any officer of the Corporation chosen by the Board of Directors, shall act as chairman of the meeting. The Secretary, or in the absence of the Secretary an Assistant Secretary, shall act as secretary of the meeting, but in the absence of the Secretary and any Assistant Secretary the chairman of the meeting may appoint any person to act as secretary of the meeting.

 

 

 

(b)     The Board of Directors, in advance of any meeting of stockholders, may, and shall if required by law, appoint one (1) or more inspector(s), who may include individual(s) who serve the Corporation in other capacities, including without limitation as officers, employees or agents, to act at the meeting of stockholders and make a written report thereof. The Board of Directors may designate one (1) or more persons as alternate inspector(s) to replace any inspector who fails to act. If no inspector or alternate has been appointed or is able to act at a meeting of stockholders, the chairman of the meeting shall appoint one (1) or more inspector(s) to act at the meeting. Each inspector, before discharging his or her duties, shall take and sign an oath to faithfully execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspector(s) or alternate(s) shall have the duties prescribed pursuant to Section 231 of the DGCL or other applicable law.

 

(c)     The Board of Directors of the Corporation shall be entitled to make such rules or regulations for the conduct of meetings of the stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the Corporation and their duly authorized and constituted proxies and such other persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at the meeting shall be announced at the meeting. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of the stockholders shall not be required to be held in accordance with rules of parliamentary procedure.

 

2.14     Postponement and Cancellation of Meeting. Any previously scheduled annual or special meeting of stockholders may be postponed, and any previously scheduled annual or special meeting of stockholders may be cancelled, by resolution of the Board of Directors upon public notice given prior to the time previously scheduled for such meeting.

 

ARTICLE III
DIRECTORS

 

3.1     General Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, except as may be otherwise provided in the DGCL or in the Certificate of Incorporation. The Board of Directors may adopt such rules and procedures, not inconsistent with the Certificate of Incorporation, these Bylaws or applicable law, as it may deem proper for the conduct of its meetings and the management of the Corporation, except as may be otherwise provided by the DGCL or by the Certificate of Incorporation.

 

3.2     Number, Term of Office and Qualifications. The Board of Directors shall consist of one or more members, the number thereof to be determined from time to time by resolution of the Board of Directors. Each director shall hold office until a successor is duly elected and qualified or until the director’s earlier death, resignation, disqualification or removal. Directors shall be natural persons, but need not be stockholders of the Corporation unless otherwise required by the Certificate of Incorporation.

 

3.3     Vacancies. Unless otherwise provided in the Certificate of Incorporation and subject to the rights of the holders of any series of preferred stock then outstanding, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholders, be filled only by the affirmative vote of a majority of the directors then in office, even if less than a quorum of the Board of Directors. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director’s successor shall have been elected and qualified.

 

 

 

3.4     Resignation. Any director may resign at any time by delivering his or her notice in writing or by electronic transmission to theSecretary, such resignation to specify whether it will be effective at a particular time, upon receipt by the Secretary or at the pleasure of the Board of Directors. If no such specification is made, it shall be deemed effective at the pleasure of the Board of Directors. Verbal resignation shall not be deemed effective until confirmed by the director in writing or by electronic transmission to the Secretary. When one or more directors shall resign from the Board of Directors effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have the power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his or her successor shall have been duly elected and qualified.

 

3.5     Removal. Subject to the Certificate of Incorporation, any director or the entire Board of Directors may be removed, with or without cause, by the affirmative vote of the holders of a majority of the voting power of all of then outstanding shares of capital stock of the Corporation then entitled to vote in the election of directors, voting together as a single class. No reduction of the authorized number of directors shall have the effect of removing any director prior to the expiration of such director’s term of office.

 

3.6     Meetings.

 

(a)     Unless otherwise restricted by the Certificate of Incorporation, regular meetings of the Board of Directors may be held at any time or date and at any place within or without the State of Delaware which has been designated by the Board of Directors and publicized among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record and communicate messages, facsimile, telegraph or telex, or by electronic mail or other electronic means. No further notice shall be required for regular meetings of the Board of Directors.

 

(b)     Unless otherwise restricted by the Certificate of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State of Delaware whenever called by the Chairman of the Board of Directors, the Chief Executive Officer, or a majority of the directors then in office.

 

(c)     Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or other communications equipment pursuant to which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting.

 

(d)     Notice of the time and place of all special meetings of the Board of Directors shall be given to each director (i) by giving notice to such director in person or by telephone, including a voice messaging system or other system designed to record and communicate messages, during normal business hours, at least twenty-four (24) hours before the meeting, (ii) by sending a telegram or delivering notice by facsimile transmission, by electronic mail or by hand, to such director at his or her last known business or home address, during normal business hours, at least twenty-four (24) hours before the meeting, or (iii) by mailing notice, via first class United States mail, to such director at his or her last known business or home address at least three (3) days in advance of the meeting. Notice of any meeting may be waived in writing, or by electronic transmission, at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Notice of a special meeting of the Board of Directors need not specify the purpose of the meeting.

 

 

 

(e)     The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though had at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present who did not receive notice shall sign a written waiver of notice or shall waive notice by electronic transmission. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors need be specified in any written waiver of notice or any waiver by electronic transmission.

 

3.7     Quorum and Voting.

 

(a)     Unless the Certificate of Incorporation requires a greater number, a quorum of the Board of Directors shall consist of a majority of the directors then in office. At any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting.

 

(b)     At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present at the meeting, unless a different vote be required by law, the Certificate of Incorporation or these Bylaws.

 

3.8     Action Without Meeting. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission, and such writing or writings or transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Any person (whether or not then a director) may provide, whether through instruction to an agent or otherwise, that a consent to action will be effective at a future time (including a time determined upon the happening of an event), no later than 60 days after such instruction is given or such provision is made and such consent shall be deemed to have been given at such effective time so long as such person is then a director and did not revoke the consent prior to such time. Any such consent shall be revocable prior to its becoming effective.

 

3.9     Fees and Compensation. Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors, or any committee thereof, including, if so approved by resolution of the Board of Directors or such committee, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the Corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor.

 

3.10     Committees.

 

(a)     The Board of Directors may, from time to time, appoint such committees as may be permitted by law. Such committees appointed by the Board of Directors shall consist of one (1) or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees, but no committee shall have the power or authority in reference to (i) approving or adopting, or recommending to the stockholders, any action or matter expressly required by the DGCL to be submitted to stockholders for approval, or (ii) adopting, amending or repealing any provision of these Bylaws.

 

(b)     The Board of Directors, subject to any requirements of any outstanding series of preferred stock and the provisions of subsections (a) and (b) of this Section 3.10, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his or her death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he, she or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.

 

 

 

(c)     Unless the Board of Directors shall otherwise provide, regular meetings of any committee appointed pursuant to this Section 3.10 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by any director who is a member of such committee, upon notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Unless otherwise provided by the Board of Directors in the resolutions authorizing the creation of the committee, a majority of the members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee.

 

3.11     Organization. At every meeting of the directors, the Chairman of the Board of Directors, or, if a Chairman of the Board of Directors has not been appointed or is absent, the Vice Chairman of the Board of Directors, or if a Vice Chairman of the Board of Directors has not been appointed or is absent, the Chief Executive Officer (if a director), or if the Chief Executive Officer is absent, or, in the absence of any such person, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in the absence of the Secretary an Assistant Secretary, shall act as secretary of the meeting, but in the absence of the Secretary and any Assistant Secretary the chairman of the meeting may appoint any person to act as secretary of the meeting.

 

ARTICLE IV
OFFICERS

 

4.1     Positions; Election and Qualification. The officers of the Corporation shall be elected annually by the Board of Directors and shall include a President or Chief Executive Officer (“Chief Executive Officer”), a Chief Financial Officer, a Treasurer and a Secretary. The Board of Directors, in its discretion, may also elect a Chairman (who must be a director), one or more Vice Chairmen (who must be directors) and one or more Vice Presidents, Assistant Treasurers, Assistant Secretaries and other officers. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any two or more offices may be held by the same person. No officer need be a stockholder.

 

4.2     Term. Each officer of the Corporation shall hold office at the pleasure of the Board of Directors and until such officer’s successor is elected and qualified or until such officer’s earlier death, resignation or removal, subject to the rights, if any, of an officer under contract of employment. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors. The election or appointment of an officer shall not of itself create contract rights

 

4.3     Duties.

 

(a)     The Chairman of the Board of Directors shall, if present, preside at meetings of the Board of Directors and stockholders and exercise and perform such other powers and duties as may from time to time be assigned to him or her by the Board of Directors or as may be prescribed by these Bylaws.

 

 

 

(b)     Subject to such supervisory powers, if any, as the Board of Directors may give to the Chairman of the Board of Directors, the Chief Executive Officer shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and affairs of the Corporation and shall report directly to the Board of Directors. All other officers, officials, employees and agents shall report directly or indirectly to the Chief Executive Officer. The Chief Executive Officer shall see that all orders and resolutions of the Board of Directors are carried into effect.

 

(c)     In the absence or disability of the Chief Executive Officer, the Vice President(s), if any, in order of their rank as fixed by the Board of Directors or, if not ranked, a Vice President designated by the Board of Directors, shall perform all the duties of the Chief Executive Officer and, when so acting, shall have all the powers of, and be subject to all the restrictions upon, the Chief Executive Officer. The Vice President(s) shall have such other powers and perform such other duties as form time to time may be prescribed for them respectively by the Board of Directors, these Bylaws, the Chairman of the Board of Directors, the Chief Executive Officer. The Board of Directors may designate one or more Executive Vice Presidents or Senior Vice Presidents or may otherwise specify the order of seniority of the Vice Presidents.

 

(d)     The Chief Financial Officer shall keep and maintain, or cause to be kept and maintained, adequate and correct books and records of accounts of the properties and business transactions of the Corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital and retained earnings. The Chief Financial Officer shall deposit all money and other valuables in the name and to the credit of the Corporation with such depositaries as may be designated by the Board of Directors or Chief Executive Officer. The Chief Financial Officer shall disburse the funds of the Corporation as may be ordered by the Board of Directors, shall render to the Board of Directors and Chief Executive Officer, whenever they request, an account of all of his or her transactions as Chief Financial Officer and of the financial condition of the Corporation, and shall have such other powers and perform such other duties as may be prescribed by the Board of Directors or these Bylaws. In lieu of any contrary resolution duly adopted by the Board of Directors, the Chief Financial Officer shall also be the Treasurer of the Corporation.

 

(e)     The Secretary shall keep or cause to be kept, at the principal executive office of the Corporation, or such other place as the Board of Directors may direct, a book of minutes of all meetings and actions of directors, committees of directors, and stockholders. The minutes shall show the time and place of each meeting, whether regular or special (and, if special, how authorized and the notice given), the names of those present at directors’ meetings or committee meetings, the number of shares present or represented at stockholders’ meetings, and the proceedings thereof.

 

The Secretary shall keep, or cause to be kept, at the principal executive office of the Corporation or at the office of the Corporation’s transfer agent or registrar, as determined by resolution of the Board of Directors, a share register, or a duplicate share register, showing the names of all stockholders and their addresses, the number and classes of shares held by each, the number and date of certificates evidencing such shares, and the number and date of cancellation of every certificate surrendered for cancellation.

 

The Secretary shall give, or cause to be given, notice of all meetings of the stockholders, the Board of Directors and any committee(s) of the Board of Directors, required to be given by law or by these Bylaws. The Secretary shall keep the seal of the Corporation, if one be adopted, in safe custody and shall have such other powers and perform such other duties as may be prescribed by the Board of Directors or by these Bylaws.

 

(f)     The Vice Chairman of the Board, if any, shall, in the absence of the Chairman of the Board, or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the Chairman of the Board and shall perform such other duties and have such other powers as the Board of Directors may from time to time prescribe.

 

 

 

(g)     The Assistant Secretary(ies), if any, in the order determined by the Board of Directors (or if there be no such determination, then in the order of their election) shall, in the absence of the Secretary or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the Secretary and shall perform such other duties and have such other powers as the Board of Directors may from time to time prescribe.

 

(h)     The Assistant Treasurer(s), if any, in the order determined by the Board of Directors (or if there be no such determination, then in the order of their election), shall, in the absence of the Chief Financial Officer or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the Chief Financial Officer and shall perform such other duties and have such other powers as the Board of Directors may from time to time prescribe.

 

4.4     Delegation of Authority. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof.

 

4.5     Resignations. Any officer may resign at any time by giving notice in writing or by electronic transmission to the Chairman of the Board, or to the Chief Executive Officer or to the Secretary. Verbal resignation shall not be deemed effective until confirmed by the officer in writing or by electronic transmission to the Chairman of the Board, Chief Executive Officer or Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the Corporation under any contract with the resigning officer.

 

4.6 Removal. Subject to the rights, if any, of an officer under contract of employment, any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or superior officers upon whom such power of removal may have been conferred by the Board of Directors.

 

ARTICLE V

EXECUTION OF CORPORATE INSTRUMENTS AND VOTING

OF SECURITIES OWNED BY THE CORPORATION

 

5.1     Execution of Corporate Instruments. The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the Corporation any corporate instrument or document, or to sign on behalf of the Corporation the corporate name without limitation, or to enter into contracts on behalf of the Corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the Corporation.

 

All checks and drafts drawn on banks or other depositaries on funds to the credit of the Corporation or in special accounts of the Corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do.

 

Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.

 

5.2     Voting of Securities Owned by the Corporation. All stock and other securities of other Corporations owned or held by the Corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer or any Vice President.

 

 

 

ARTICLE VI

SHARES OF STOCK

 

6.1     Form and Execution of Certificates. Shares of stock of the Corporation shall be represented by certificates, or shall be uncertificated. Certificates for the shares of stock of the Corporation, if any, shall be in such form as is consistent with the Certificate of Incorporation and applicable law. Every holder of stock represented by certificate shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairman of the Board of Directors, or the Chief Executive Officer or any Vice President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him or her in the Corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he or she were such officer, transfer agent, or registrar at the date of issue.

 

6.2     Transfers of Stock. Transfers of record of shares of stock of the Corporation shall be made only upon its books by the holders thereof, in person or by attorney duly authorized, and, in the case of stock represented by certificate, upon the surrender of a properly endorsed certificate or certificates for a like number of shares. To the extent designated by the Chief Executive Officer or any Vice President or the Treasurer of the Corporation, the Corporation may recognize the transfer of fractional uncertificated shares, but shall not otherwise be required to recognize the transfer of fractional shares. The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.

 

6.3     Transfer Agents and Registrars. The Board of Directors may appoint, or authorize any officer or officers to appoint, one or more transfer agents and one or more registrars.

 

6.4     Lost, Stolen or Destroyed Certificates. A new certificate or certificates or uncertificated shares shall be issued in place of any certificate or certificates theretofore issued by the Corporation alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed. The Corporation may require, as a condition precedent to the issuance of a new certificate or certificates or uncertificated shares, the owner of such lost, stolen or destroyed certificate or certificates, or the owner’s legal representative, to agree to indemnify the Corporation in such manner as it shall require or to give the Corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen or destroyed.

 

6.5     Fixing Record Dates.

 

(a)     In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the determination of stockholders entitled to vote at the adjourned meeting and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for the determination of stockholders entitled to vote therewith at the adjourned meeting.

 

 

 

(b)     In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. If no record date has been fixed by the Board of Directors, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting: (i) when no prior action by the Board of Directors is required by law, the record date for such purpose shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery (by hand, or by certified or registered mail, return receipt requested) to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of the stockholders are recorded and (ii) if prior action by the Board of Directors is required by law, the record date for such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.

 

(c)     In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

 

6.6     Registered Stockholders. The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by applicable law.

 

ARTICLE VII

OTHER SECURITIES OF THE CORPORATION

 

7.1     Execution of Other Securities. All bonds, debentures and other corporate securities of the Corporation, other than stock certificates (covered in Section 6.1), may be signed by the Chairman of the Board of Directors, the Chief Executive Officer, the President or any Vice President, or such other person as may be authorized by the Board of Directors, and the corporate seal, if any, may be impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant Treasurer; provided, however, that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and, if applicable, attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the Corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the Corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the Corporation.

 

ARTICLE VIII
DIVIDENDS

 

8.1     Declaration of Dividends. Dividends upon the capital stock of the Corporation, subject to the provisions of the Certificate of Incorporation and applicable law, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Certificate of Incorporation and applicable law.

 

 

 

8.2     Dividend Reserve. Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the Corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created.

 

ARTICLE IX

GENERAL PROVISIONS

 

9.1     Fiscal Year. The fiscal year of the Corporation shall be fixed from time to time by resolution of the Board of Directors.

 

9.2     Corporate Seal. The Corporation may, but need not, have a corporate seal. In the event the Corporation has a seal, the seal need not be affixed for any contract, resolution or other document executed by or on behalf of the Corporation to be valid and duly authorized.

 

9.3 Notices.

 

(a)     Written notice to stockholders of stockholder meetings shall be given as provided in Section 2.4 herein. Without limiting the manner by which notice may otherwise be given effectively to stockholders under any agreement or contract with such stockholder, and except as otherwise required by law, written notice to stockholders for purposes other than stockholder meetings may be sent by United States mail or nationally recognized overnight courier, or by facsimile, telegraph or telex or by electronic mail or other electronic means.

 

(b)     Notice to directors of special meetings shall be given as provided in Section 3.7(d) herein. Subject to the preceding sentence and except as expressly stated otherwise herein, notice may otherwise be given by the methods stated in subsection (a) above.

 

(c)     An affidavit of mailing, executed by a duly authorized and competent employee of the Corporation or its transfer agent appointed with respect to the class of stock affected, or other agent, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained.

 

(d)     It shall not be necessary that the same method of giving notice be employed in respect of all recipients of notice, but one permissible method may be employed in respect of any one or more recipients, and any other permissible method or methods may be employed in respect of any other or others.

 

(e)     Whenever notice is required to be given, under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, to any person with whom communication is unlawful, the giving of such notice to such person shall not be required and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event the action taken by the Corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.

 

 

 

(f)     Whenever notice is required to be given, under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, to any stockholder to whom (i) notice of two (2) consecutive annual meetings, or (ii) all, and at least two (2), payments (if sent by first-class mail) of dividends or interest on securities during a twelve (12) month period, have been mailed addressed to such person at such person’s address as shown on the records of the Corporation and have been returned undeliverable, the giving of such notice to such person shall not be required. Any actions or meeting which shall be taken or held without notice to such person shall have the same force and effect as if such notice had been duly given. If any such person shall deliver to the Corporation a written notice setting forth such person’s then current address, the requirement that notice be given to such person shall be reinstated. In the event that the action taken by the Corporation is such as to require the filing of a certificate under any provision of the DGCL, the certificate need not state that the Corporation did not give notice to persons not required to be given notice pursuant to Section 230(b) of the DGCL. The exception in clause (i) above to the requirement that notice be given shall not be applicable to any notice returned as undeliverable if the notice was given by electronic transmission.

 

(g)     Except as otherwise prohibited under the DGCL, any notice given under the provisions of the DGCL, the Certificate of Incorporation or these Bylaws shall be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Such consent shall be deemed to have been given if such stockholder fails to object in writing to the Corporation within sixty (60) days of having been given notice by the Corporation of its intention to send the single notice. Any consent shall be revocable by the stockholder by written notice to the Corporation.

 

(h)     Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation or these Bylaws shall be effective if given by a form of electronic transmission previously consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice to the Corporation. Any such consent shall be deemed revoked if (i) the Corporation is unable to deliver by electronic transmission two (2) consecutive notices given by the Corporation in accordance with such consent, and (ii) such inability becomes known to the Secretary or an Assistant Secretary of the Corporation, the transfer agent or other person responsible for the giving of notice; provided, however, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.

 

Notice given pursuant to the above paragraph shall be deemed given (i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice, (ii) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice, (iii) if by a posting on an electronic network together with a separate notice to the stockholder of such specific posting, upon the later of (A) such posting and (B) the giving of such separate notice, and (iv) if by any other form of electronic transmission, when directed to the stockholder. An affidavit of the Secretary or Assistant Secretary, the transfer agent or other agent of the Corporation that the notice has been given by a form of electronic transmission shall in the absence of fraud, be prima facie evidence of the facts stated therein.

 

For purposes of these Bylaws, “electronic transmission” means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process. This Section 9.3 shall not apply to Section 164 (failure to pay for stock; remedies), Section 296 (adjudication of claims; appeal), Section 311 (revocation of voluntary dissolution), Section 312 (renewal, revival, extension and restoration of certificate of incorporation) or Section 324 (attachment of shares of stock) of the DGCL.

 

9.4     Construction. Unless the context requires otherwise, the general provisions, rules of construction and definitions in the DGCL shall govern the construction of these Bylaws. The singular number includes the plural, and the plural number includes the singular. All pronouns used in these Bylaws shall be deemed to refer to the masculine, feminine and/or neuter, as the identity of the person or persons so designated may require.

 

9.5     Conflict With Applicable Law or Certificate of Incorporation. These Bylaws are adopted subject to any applicable law and the Certificate of Incorporation. Whenever these Bylaws may conflict with any applicable law or the Certificate of Incorporation, such conflict shall be resolved in favor of such law or the Certificate of Incorporation.

 

 

 

ARTICLE X

INDEMNIFICATION AND ADVANCEMENT OF EXPENSES

 

10.1     Right to Indemnification. The Corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person (an “Indemnitee”) who was or is made or is threatened to be made a party or is otherwise involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director, officer, employee or agent of the Corporation or, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (any such entity, an “Other Entity”), against all liability and loss suffered (including, but not limited to expenses (including but not limited to, attorneys’ fees and expenses), judgments, fines and amounts paid in settlement actually and reasonably incurred by such Indemnitee in connection with any such Proceeding) provided, that the Indemnitee acted in good faith and in a manner such Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any Proceeding that is criminal in nature, had no reasonable cause to believe that his or her conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, does not, of itself, create a presumption that the Indemnitee did not act in good faith and in a manner in which he or she reasonably believed to be in or not opposed to the best interests of the Corporation, or that, with respect to any criminal proceeding he or she had reasonable cause to believe that his or her conduct was unlawful. The Corporation shall not indemnify an Indemnitee for any claim, issue or matter as to which the Indemnitee has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the Corporation or for any amounts paid in settlement to the Corporation, unless and only to the extent that the court in which the Proceeding was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the Indemnitee is fairly and reasonably entitled to indemnity for such amounts as the court deems proper.

 

10.2     Advancement of Expenses. The Corporation shall to the fullest extent not prohibited by applicable law pay the expenses (including attorneys’ fees) incurred by an Indemnitee in defending any Proceeding in advance of its final disposition, provided, however, that, to the extent required by law, such payment of expenses in advance of the final disposition of the Proceeding shall be made only upon receipt of an undertaking by the Indemnitee to repay all amounts advanced if it should be ultimately determined that the Indemnitee is not entitled to be indemnified under this Article X or otherwise.

 

10.3     Former Directors, Officers, Employees and Agents. Indemnification pursuant to this Article X shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Corporation or member, manager or managing member of a predecessor limited liability company or affiliate of such limited liability company or a director, officer, employee, agent, partner, member, manager or fiduciary of, or to serve in any other capacity for, another corporation or any partnership, joint venture, limited liability company, trust, or other enterprise and shall inure to the benefit of his or her heirs, executors and administrators.

 

10.4     Claims. If a claim for indemnification (following the final disposition of the Proceeding with respect to which indemnification is sought, including any settlement of such Proceeding) or advancement of expenses under this Article X is not paid in full within sixty (60) days after a written claim therefor by the Indemnitee has been received by the Corporation, the Indemnitee may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim to the fullest extent permitted by applicable law. In any such action the Corporation shall have the burden of proving that the Indemnitee is not entitled to the requested indemnification or advancement of expenses under this Article X and applicable law.

 

10.5     Non-Exclusivity of Rights. The rights conferred on any Indemnitee by this Article X shall not be exclusive of any other rights which such Indemnitee may have or hereafter acquire under any statute, the Certificate of Incorporation, these Bylaws, or any agreement, vote of stockholders or disinterested directors or otherwise.

 

10.6     Insurance. The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the Corporation would have the power to indemnify such person against such liability under this Article X, the DGCL or otherwise.

 

 

 

10.7     Amendment or Repeal. Any right to indemnification or to advancement of expenses of any Indemnitee arising hereunder shall not be eliminated or impaired by an amendment to or repeal of this Article X after the occurrence of the act or omission that is the subject of the Proceeding for which indemnification or advancement of expenses is sought.

 

10.8     Saving Clause. If this Article X or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each director, officer, employee and agent to the fullest extent not prohibited by any applicable portion of this Article X that shall not have been invalidated, or by any other applicable law. If this Article X shall be invalid due to the application of the indemnification provisions of another jurisdiction, then the Corporation shall indemnify each director, officer, employee and agent to the fullest extent under any other applicable law.

 

ARTICLE XI

EXCLUSIVE JURISDICTION FOR CERTAIN ACTIONS

 

11.1     Exclusive Jurisdiction for Certain Actions. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim for breach of a fiduciary duty owed by any director, officer, employee or agent of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws of the Corporation or (iv) any action asserting a claim governed by the internal affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein.

 

ARTICLE XII
AMENDMENTS

 

12.1     Amendments. The Board of Directors is expressly empowered to adopt, amend or repeal these Bylaws or adopt new Bylaws of the Corporation. Any adoption, amendment or repeal of these Bylaws or adoption of new Bylaws of the Corporation by the Board of Directors shall require the approval of a majority of the directors then in office. Notwithstanding the foregoing, the stockholders of the Corporation shall also have power to adopt, amend or repeal the Bylaws of the Corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Corporation required by law or by the Certificate of Incorporation, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws of the Corporation.

 

Adopted as of June 18, 2015.

 

Amended: January 8, 2016; March 18, 2022; August 16, 2023.

 

 

 
EX-4.1 6 ex_562001.htm EXHIBIT 4.1 ex_562001.htm

Exhibit 4.1

 

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING THIS WARRANT UNDER THE ACT AND ANY OTHER APPLICABLE SECURITIES LAWS, OR (2) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

CERVOMED INC.

 

WARRANT TO PURCHASE SHARES OF COMMON STOCK

 

__________          Warrant No. __

 

For value received, CervoMed, Inc., a Delaware corporation (the “Company”), hereby certifies that ______ or his or her registered transferees, successors or assigns (each person or entity holding all or part of this Warrant being referred to as a “Holder”), is the registered holder of warrants (the “Warrants”) to subscribe for and purchase ______________ (____) shares (as adjusted pursuant to Section 3 hereof, the “Warrant Shares”) of the fully paid and nonassessable common stock, $0.001 par value per share, of the Company, at a purchase price per share initially equal to __________ ($_____) (the “Warrant Price”) on or before, 5:00 P.M. Eastern Time, on April 2, 2028 (the “Expiration Date”), subject to the provisions and upon the terms and conditions hereinafter set forth; provided, however, that in the event that any portion of this Warrant is unexercised as of the Expiration Date, the terms of below shall apply. As used in this Warrant, the term “Business Day” means any day other than a Saturday or Sunday on which commercial banks located in New York, New York are open for the general transaction of business.

 

1.    Exercise.

 

(a)    Method of Exercise; Payment; Issuance of New Warrant.

 

(i)    Subject to the provisions hereof, the Holder may exercise this Warrant, in whole or in part and from time to time, by the surrender of this Warrant (with the Notice of Exercise attached hereto as Appendix A duly executed) at the principal office of the Company, or such other office or agency of the Company as it may reasonably designate by written notice to the Holder, during normal business hours on any Business Day, and the payment by the Holder by cash, certified check payable to the Company or wire transfer of immediately available funds to an account designated to the exercising Holder by the Company of an amount equal to the then applicable Warrant Price multiplied by the number of Warrant Shares then being purchased, or in the event of a cashless exercise pursuant to Section 1(c) below, with the Net Issue Election Notice attached hereto as Appendix B duly executed and completed. On the date on which the Holder shall have satisfied in full the Holder’s obligations set forth herein regarding an exercise of this Warrant (provided such date is prior to the Expiration Date), the Holder (or such other person or persons as directed by the Holder) shall be treated for all purposes as the holder of record of such Warrant Shares as of the close of business on such date.

 

 

 

 

(ii)    In the event of any exercise of the rights represented by this Warrant, certificates for the whole number of shares of Common Stock so purchased shall be delivered to the Holder (or such other person or persons as directed by the Holder) as promptly as is reasonably practicable (but not later than three (3) Business Days) after such exercise at the Company’s expense, and, unless this Warrant has been fully exercised, a new Warrant representing the whole number of Warrant Shares, if any, with respect to which this Warrant shall not then have been exercised shall also be issued to the Holder as soon as reasonably practicable thereafter, (but not later than three (3) Business Days), after such exercise.

 

(b)    Automatic Exercise. If any portion of this Warrant remains unexercised as of either (i) the Expiration Date or (ii) the expiration of the Mandatory Exercise Period and, in either such case, the Fair Market Value (as defined below) of one share of Common Stock as of the such date is greater than the applicable Warrant Price as of the such date, then this Warrant shall be deemed to have been exercised automatically immediately prior to the close of business (i) on the Expiration Date (or, in the event that the Expiration Date is not a Business Day, the immediately preceding Business Day) or (ii) immediately prior to the expiration of the Mandatory Exercise Period, as applicable (the “Automatic Exercise Date”), in the manner provided in Section 1(c) below, and the Holder (or such other person or persons as directed by the Holder) shall be treated for all purposes as the holder of record of such Warrant Shares as of the close of business on such Automatic Exercise Date. This Warrant shall be deemed to be surrendered to the Company on the Automatic Exercise Date by virtue of this Section 1(b) without any action by the Holder. As promptly as is reasonably practicable on or after the Automatic Exercise Date, but in no event prior to the date on which this Warrant is surrendered to the Company at the principal office of the Company, or such other office or agency of the Company as it may reasonably designate by written notice to the Holder, during normal business hours on any Business Day, the Company at its expense shall issue and deliver to the Holder (or such other person or persons as directed by the Holder) a certificate or certificates for the number of Warrant Shares issuable upon such exercise, in accordance with Section 1(c).

 

- 2 -

 

(c)    Cashless Right to Convert Warrant into Common Stock. In addition to and without limiting the rights of the Holder hereof under the terms of this Warrant, the Holder may elect to receive, without the payment by the Holder of the Warrant Price, Warrant Shares equal to the value of this Warrant or any portion hereof by the surrender of this Warrant (or such portion of this Warrant being so exercised) together with the Net Issue Election Notice annexed hereto as Appendix B duly executed and completed, at the office of the Company, or such other office or agency of the Company as it may reasonably designate by written notice to the Holder, during normal business hours on any Business Day. Thereupon, the Company shall issue to the Holder such number of fully paid, validly issued and nonassessable Warrant Shares, as is computed using the following formula:

 

X= Y(A-B)

A

 

where

 

 

X =

the number of shares of Common Stock to be issued to the Holder (or such other person or persons as directed by the Holder) upon such exercise of the rights under this Section 1(c)

 

 

Y =

=the total number of shares of Common Stock covered by this Warrant which the Holder has surrendered for cashless exercise

 

 

A =

the “Fair Market Value” of one share of Common Stock on the date that the Holder delivers the Net Issue Election Notice to the Company as provided herein

 

 

B =

the Warrant Price in effect under this Warrant on the date that the Holder delivers the Net Issue Election Notice to the Company as provided herein

 

The “Fair Market Value” of a share of Common Stock as of a particular date (the “Valuation Date”) shall mean the following: (y) if the Common Stock is then listed on a stock exchange or quoted on a quotation system, the closing sale price of one share of Common Stock on such exchange or system on the last trading day prior to the Valuation Date; or (z) if the Common Stock is not then listed on a stock exchange or quoted on a quotation system, the Fair Market Value of one share of Common Stock as of the Valuation Date shall be determined by the Board of Directors of the Company (the “Board”) in its reasonable and good faith judgment. The Board shall respond promptly in writing to an inquiry by the Holder prior to the exercise hereunder as to the Fair Market Value of a share of Common Stock.

 

(d)    Mandatory Exercise. So long as this Warrant shall be outstanding, if the Company proposes to enter into a Mandatory Exercise Transaction (as hereinafter defined), then in any such case, the Company shall cause to be mailed by certified mail to the Holder, at least twenty (20) days prior to the date such proposed Mandatory Exercise Transaction is to be effectuated, a notice containing (i) a brief description of the proposed Mandatory Exercise Transaction; and (ii) the date upon which such proposed Mandatory Exercise Transaction is to take place. The failure to give such notice, however, shall not affect the validity of any proposed Mandatory Exercise Transaction for which the notice was required to be given but shall relieve the Holder of its obligation to exercise the Warrant pursuant to this provision. During the period beginning on the date of Holder’s receipt of such notice and ending on the date which is two (2) days prior to the date upon which such proposed Mandatory Exercise Transaction is to take place, as set forth in the notice (the “Mandatory Exercise Period”), Holder must exercise its right, in accordance with all applicable conditions of exercise set forth in this Warrant, to purchase Warrant Shares which Holder is entitled to purchase hereunder, and if Holder fails to so exercise such right within the Mandatory Exercise Period (unless the Company has failed to give the notice required hereunder), all Warrant Shares for which Holder has not exercised its right to receive hereunder shall expire. For purposes hereof, a “Mandatory Exercise Transaction” shall mean any of the following:

 

(i)    any merger or consolidation of the Company with or into any corporation or other entity that is not a wholly-owned subsidiary of the Company, other than a merger in which the Company or a wholly-owned subsidiary of the Company is the surviving entity; or

 

- 3 -

 

(ii)    any sale, exclusive license or other disposition of all or substantially all of the assets of the Company to a person or entity other than a wholly-owned subsidiary of the Company.

 

2.    Reservation of Shares; Stock Fully Paid; Listing. The Company shall keep reserved a sufficient number of shares of the authorized and unissued shares of Common Stock, to provide for the exercise of the rights of purchase represented by this Warrant in compliance with its terms. All Warrant Shares issued upon exercise of this Warrant shall be, at the time of delivery of the certificates for such Warrant Shares upon payment in full of the Exercise Price therefor in accordance with the terms of this Warrant (or proper exercise of the cashless exercise rights contained in Section 3(c) hereof), duly authorized, validly issued, fully paid and non-assessable shares of Common Stock of the Company. The Company shall during all times prior to the Expiration Date when the shares of Common Stock issuable upon the exercise of this Warrant are authorized for quotation or listing on a stock exchange or quotation system, keep the shares of Common Stock issuable upon the exercise of this Warrant authorized for quotation such exchange or system, as the case may be.

 

3.    Adjustments and Distributions. The number and kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows:

 

(a)    Dividends and Distributions. If the Company shall at any time or from time to time while this Warrant is outstanding, pay a dividend or make a distribution on its Common Stock in shares of Common Stock, subdivide its outstanding shares of Common Stock into a greater number of shares or combine its outstanding shares of Common Stock into a smaller number of shares, then the number of Warrant Shares purchasable upon exercise of this Warrant and the Warrant Price in effect immediately prior to the date upon which such change shall become effective shall be proportionally adjusted by the Company so that the Holder thereafter exercising this Warrant shall be entitled to receive the number of shares of Common Stock or other capital stock which the Holder would have received if this Warrant had been exercised immediately prior to such event (taking into account such event) upon payment of a Warrant Price that has been proportionally adjusted to reflect such event. Such adjustments shall be made successively whenever any event listed above shall occur.

 

- 4 -

 

(b)    Reorganization. If any recapitalization, reclassification or reorganization of the capital stock of the Company (other than a change in par value or a subdivision or combination as provided for in Section 3(a) above) shall be effected in such a manner (including, without limitation, in connection with a consolidation or merger in which the Company is the continuing corporation), that holders of Common Stock shall be entitled to receive stock, securities, or other assets or property (a “Reorganization”), then, as a condition of such Reorganization, lawful and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter have the right to purchase and receive (in lieu of the shares of the Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby) such shares of stock, securities or other assets or property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby. In the event of any Reorganization, appropriate provision shall be made by the Company with respect to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation, provisions for adjustments of the Warrant Price and of the number of Warrant Shares) shall thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof. The provisions of this Section 3(b) shall similarly apply to successive Reorganizations.

 

(c)    Mergers and other Transactions. If any consolidation or merger of the Company with another entity in which the Company is not the survivor, or sale, transfer, exclusive license or other disposition of all or substantially all of the Company’s assets to another entity shall be effected, then, as a condition of such consolidation, merger, sale, transfer, exclusive license or other disposition, lawful and adequate provision shall be made whereby the Holder shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions herein specified and in lieu of the Warrant Shares immediately theretofore issuable upon exercise of this Warrant, such shares of stock, securities or assets as would have been issuable or payable with respect to or in exchange for a number of Warrant Shares equal to the number of Warrant Shares immediately theretofore issuable upon exercise of this Warrant, had such consolidation, merger, sale, transfer, exclusive license or other disposition not taken place, and in any such case appropriate provision shall be made with respect to the rights and interests of each Holder to the end that the provisions hereof (including, without limitation, provision for adjustment of the Warrant Price and of the number of Warrant Shares) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any shares of stock, securities or properties thereafter deliverable upon the exercise thereof. The Company shall not effect any such consolidation, merger, sale, transfer or other disposition unless prior to or simultaneously with the consummation thereof the successor entity (if other than the Company) resulting from such consolidation or merger, or the entity purchasing or otherwise acquiring such assets or other appropriate entity shall assume the obligation to deliver to the Holder such shares of stock, securities or assets as, in accordance with the foregoing provisions, such Holder may be entitled to purchase, and the other obligations under this Warrant. The provisions of this Section 3(c) shall similarly apply to successive consolidations, mergers, sales, transfers or other dispositions.

 

(d)    Price and Payment. In case the Company shall fix a payment date for the making of a distribution to all holders of Common Stock of evidences of indebtedness or assets (other than dividends or distributions referred to in Section 3(a) hereof), or subscription rights or warrants, the Warrant Price to be in effect after such payment date shall be determined by multiplying the Warrant Price in effect immediately prior to such payment date by a fraction, the numerator of which shall be the total number of shares of Common Stock outstanding multiplied by the Fair Market Value per share of Common Stock immediately prior to such payment date, less the fair market value (as determined by the Board in good faith) of said assets or evidences of indebtedness so distributed, or of such subscription rights or warrants, and the denominator of which shall be the total number of shares of Common Stock outstanding multiplied by such Fair Market Value per share of Common Stock immediately prior to such payment date. Such adjustment shall be made successively whenever such a payment date is fixed.

 

(i)    In the event that any dividend or distribution for which this Section 3(d) would require an adjustment is not so paid or made, the Warrant Price shall be adjusted to be the Warrant Price which would then be in effect if such dividend or distribution had not been declared.

 

- 5 -

 

(ii)    In the event that the Company implements a new shareholder rights plan, such rights plan shall provide that upon exercise of this Warrant the Holder will receive, in addition to the Common Stock issuable upon such exercise, the rights issued under such rights plan (as if the Holder had exercised this Warrant prior to implementing the rights plan and notwithstanding the occurrence of an event causing such rights to separate from the Common Stock at or prior to the time of exercise). Any distribution of rights or warrants pursuant to a shareholder rights plan complying with the requirements set forth in the immediately preceding sentence of this paragraph shall not constitute a distribution of rights or warrants for the purposes of this Section 3(d).

 

(e)    Effective Date. An adjustment pursuant to this Section 3 shall become effective immediately after the payment date in the case of each dividend or distribution and immediately after the effective date of each other event which requires an adjustment.

 

(f)    Other Shares. In the event that, as a result of an adjustment made pursuant to this Section 3, the Holder shall become entitled to receive any shares of capital stock of the Company other than shares of Common Stock, the number of such other shares so receivable upon exercise of this Warrant shall be subject thereafter to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Warrant Shares contained in this Warrant.

 

(g)    Notice of Adjustments. With each adjustment pursuant to this Section 3, the Company shall deliver a certificate signed by its chief financial or executive officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and the number of Warrant Shares purchasable hereunder after giving effect to such adjustment, which shall be mailed by first class mail, postage prepaid to the Holder.

 

4.    Transfer Taxes. The Company will pay any documentary stamp taxes attributable to the initial issuance of Warrant Shares issuable upon the exercise of the Warrant; provided, however, that the Company shall not be required to pay any tax or taxes which may be payable in respect of any transfer involved in the issuance or delivery of any certificates for Warrant Shares in a name other than that of the registered holder of this Warrant in respect of which such shares are issued, and in such case, the Company shall not be required to issue or deliver any certificate for Warrant Shares or any Warrant until the person requesting the same has paid to the Company the amount of such tax or has established to the Company’s reasonable satisfaction that such tax has been paid.

 

- 6 -

 

5.    Mutilated or Missing Warrants. In case this Warrant shall be mutilated, lost, stolen, or destroyed, the Company shall issue in exchange and substitution of and upon cancellation of the mutilated Warrant, or in lieu of and substitution for the Warrant lost, stolen or destroyed, a new Warrant of like tenor and for the purchase of a like number of Warrant Shares, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction of the Warrant, and with respect to a lost, stolen or destroyed Warrant, reasonable indemnity or bond with respect thereto, if requested by the Company.

 

6.    Fractional Shares. No fractional shares of Common Stock shall be issued in connection with any exercise or cashless exercise hereunder, and in lieu of any such fractional shares the Company shall make a cash payment therefor to the Holder (or such other person or persons as directed by the Holder) based on the Fair Market Value of a share of Common Stock on the date of exercise or cashless exercise of this Warrant.

 

7.    Compliance with Securities Act and Legends. The Holder, by acceptance hereof, agrees that this Warrant and the shares of Common Stock to be issued upon exercise hereof, are being acquired for investment and that such Holder will not offer, sell or otherwise dispose of this Warrant, or any shares of Common Stock to be issued upon exercise hereof except under circumstances which will not result in a violation of the Securities Act of 1933, as amended, or the rules and regulations promulgated thereunder, as amended (the “Act”), or any state’s securities laws. Upon exercise of this Warrant, the Holder shall confirm in writing, by executing the form attached as Schedule 1 to Appendix A hereto, that the shares of Common Stock so purchased are being acquired for investment and not with a view toward distribution or resale. All shares of Common Stock issued upon exercise of this Warrant (unless registered under the Act) shall be stamped or imprinted with a legend as follows:

 

THIS SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING THESE SECURITIES UNDER THE ACT AND ANY OTHER APPLICABLE SECURITIES LAWS, OR (2) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

8.    Rights as Stockholders. Except as expressly provided in this Warrant, no Holder, as such, shall be entitled to vote or receive dividends or be deemed the holder of Common Stock or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Holder, as such, any of the rights of a stockholder of the Company or any right to vote for the election of the directors or upon any matter submitted to stockholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or otherwise, until this Warrant shall have been exercised and the Warrant Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.

 

- 7 -

 

9.    Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the Company and the then current Holder, and such change, waiver, discharge or termination shall be binding on all future Holders.

 

10.    Notices. Unless otherwise specifically provided herein, all communications under this Warrant shall be in writing and shall be deemed to have been duly given (a) on the date personally delivered to the party to whom notice is to be given, (b) on the day of transmission if sent by facsimile transmission to a number provided to a party specifically for such purposes and the sending party receives confirmation of the completion of such transmission, (c) on the Business Day after delivery to Federal Express or similar overnight courier which utilizes a written form of receipt, or (d) on the fifth day after mailing, if mailed to the party to whom notice is to be given, by first class mail, registered or certified, postage prepaid, and properly addressed, return receipt requested, to each such Holder at its address as shown on the books of the Company or to the Company at the address indicated therefor on the signature page of this Warrant. Any party hereto may change its address for purposes of this Section 9 by giving the other party written notice of the new address in the manner set forth herein.

 

11.    Descriptive Headings. The descriptive headings contained in this Warrant are inserted for convenience only and do not constitute a part of this Warrant.

 

12.    Governing Law. The validity, interpretation and performance of this Warrant shall be governed by, and construed in accordance with, the laws of the State of Delaware applicable to contracts made and to be performed entirely within such State, regardless of the law that might be applied under principles of conflicts of law. The Company and, by accepting this Warrant, the Holder, each irrevocably submits to the exclusive jurisdiction of the courts of the State of Delaware and the United States District Court for the District of Delaware for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Warrant and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Warrant. The Company and, by accepting this Warrant, the Holder, each irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. The Company and, by accepting this Warrant, the Holder, each irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.

 

13.    Acceptance. Receipt of this Warrant by the Holder hereof shall constitute acceptance of and agreement to the foregoing terms and conditions.

 

14.    No Impairment of Rights. The Company will not, by amendment of its Certificate of Incorporation or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against material impairment.

 

- 8 -

 

15.    Assignment. A Holder may transfer its rights hereunder, in whole or in part, to any other person (other than a competitor of the Company, as determined by the Board in good faith; provided, however, __________ shall be deemed not to be a competitor), provided that written notice is given to the Company of any such transfer and such transfer is in accordance with applicable law. Upon receipt by the Company of notice by a Holder of a transfer of any portion of this Warrant, the Company shall promptly deliver to a transferee a Warrant in the form hereof exercisable for the number of Warrant Shares the right of which to purchase has been transferred. In addition to, and not in limitation of, the foregoing, a Holder that is a corporation, a partnership or a limited liability company, may distribute any portion of a warrant to its respective shareholders, partners or members.

 

* * *

 

- 9 -

 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed on its behalf by one of its officers thereunto duly authorized on the date set forth above.

 

 

CERVOMED INC.

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

John Alam, President & CEO

 

 

     

 

 

 

 

[Signature Page to Common Stock Warrant]


 

 

APPENDIX A

 

Notice of Exercise

 

To: CervoMed Inc.

 

1.         The undersigned hereby irrevocably elects to purchase [_____] shares of Common Stock of CervoMed Inc. pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full, by cash, certified check/wire transfer/surrender of the originally executed Warrant.

 

2.         Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name or names as are specified below:

 

   
   
(Name)  
   
   
(Address)  
   
  (Signature)
  (Date)

 

3.         Please issue a new Warrant of equivalent form and tenor for the unexercised portion of the attached Warrant in the name of the undersigned or in such other name as is specified below:

 

       
Date:      
       
(Warrantholder)      
       
Name: (Print)    
       
By:      

 

 

 

 

Schedule 1

 

INVESTMENT REPRESENTATION STATEMENT

 

Purchaser:    
Company: CervoMed Inc.  
Security: Common Stock  
Amount:    
Date:    

     

In connection with the purchase of the above-listed securities (the “Securities”), the undersigned (the “Purchaser”) represents to the Company as follows:

 

(a)         The Purchaser is aware of the Company’s business affairs and financial condition, and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities. The Purchaser is purchasing the Securities for its own account for investment purposes only and not with a view to, or for the resale in connection with, any “distribution” thereof for purposes of the Securities Act of 1933, as amended (the “Act”).

 

(b)         The Purchaser understands that the Securities have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Purchaser’s investment intent as expressed herein. In this connection, the Purchaser understands that, in the view of the Securities and Exchange Commission (“SEC”), the statutory basis for such exemption may be unavailable if the Purchaser’s representation was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified under applicable tax laws, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one year or any other fixed period in the future.

 

(c)         The Purchaser further understands that the Securities must be held indefinitely unless subsequently registered under the Act or unless an exemption from registration is otherwise available. In addition, the Purchaser understands that the certificate evidencing the Securities will be imprinted with the legend referred to in the Warrant under which the Securities are being purchased.

 

(d)         The Purchaser is aware of the provisions of Rule 144 and 144A, promulgated under the Act, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate of such issuer), in a non-public offering subject to the satisfaction of certain conditions, if applicable, including, among other things: The availability of certain public information about the Company, the resale occurring not less than one (1) year after the party has purchased and paid for the securities to be sold; the sale being made through a broker in an unsolicited “broker’s transaction” or in transactions directly with a market maker (as said term is defined under the Securities Exchange Act of 1934, as amended) and the amount of securities being sold during any three-month period not exceeding the specified limitations stated therein.

 

 

 

(e)         The Purchaser further understands that at the time it wishes to sell the Securities there may be no public market upon which to make such a sale, and that, even if such a public market then exists, the Company may not be satisfying the current public information requirements of Rule 144 and 144A, and that, in such event, the Purchaser may be precluded from selling the Securities under Rule 144 and 144A even if the one-year minimum holding period had been satisfied.

 

(f)         The Purchaser further understands that in the event all of the requirements of Rule 144 and 144A are not satisfied, registration under the Act, compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rule 144 is not exclusive, the Staff of the SEC has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rule 144 will have a substantial burden or proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk.

 

 

 

Purchaser:                                                                         

 

 

 

 

APPENDIX B

 

Net Issue Election Notice

 

To:         [                                         ]

 

Date:         [                                      ]

 

The undersigned hereby elects under Section [__] of this Warrant to surrender the right to purchase [______________] shares of Common Stock pursuant to this Warrant and hereby requests the issuance of [______________] shares of Common Stock. The certificate(s) for the shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated below.

 

   
Signature  
   
   
Name for Registration  
   
   
Mailing Address  

 

 
EX-4.2 7 ex_562002.htm EXHIBIT 4.2 ex_562002.htm

Exhibit 4.2

 

 

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING THIS WARRANT UNDER THE ACT AND ANY OTHER APPLICABLE SECURITIES LAWS, OR (2) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

CERVOMED INC.

 

WARRANT TO PURCHASE SHARES OF COMMON STOCK

 

________________ Warrant No. __

        

For value received, CervoMed Inc., a Delaware corporation (the “Company”), hereby certifies that ____________, a _______________, or its registered transferees, successors or assigns (each person or entity holding all or part of this Warrant being referred to as a “Holder”), is the registered holder of warrants (the “Warrants”) to subscribe for and purchase _______________ (_____) shares (as adjusted pursuant to Section 3 hereof, the “Warrant Shares”) of the fully paid and nonassessable common stock, $0.001 par value per share, of the Company, at a purchase price per share initially equal to _____________ ($___) (the “Warrant Price”) on or before, 5:00 P.M. Eastern Time, on April 2, 2028 (the “Expiration Date”), subject to the provisions and upon the terms and conditions hereinafter set forth; provided, however, that in the event that any portion of this Warrant is unexercised as of the Expiration Date, the terms of below shall apply. As used in this Warrant, the term “Business Day” means any day other than a Saturday or Sunday on which commercial banks located in New York, New York are open for the general transaction of business.

 

1.    Exercise.

 

(a)    Method of Exercise; Payment; Issuance of New Warrant.

 

(i)    Subject to the provisions hereof, the Holder may exercise this Warrant, in whole or in part and from time to time, by the surrender of this Warrant (with the Notice of Exercise attached hereto as Appendix A duly executed) at the principal office of the Company, or such other office or agency of the Company as it may reasonably designate by written notice to the Holder, during normal business hours on any Business Day, and the payment by the Holder by cash, certified check payable to the Company or wire transfer of immediately available funds to an account designated to the exercising Holder by the Company of an amount equal to the then applicable Warrant Price multiplied by the number of Warrant Shares then being purchased, or in the event of a cashless exercise pursuant to Section 1(c) below, with the Net Issue Election Notice attached hereto as Appendix B duly executed and completed. On the date on which the Holder shall have satisfied in full the Holder’s obligations set forth herein regarding an exercise of this Warrant (provided such date is prior to the Expiration Date), the Holder (or such other person or persons as directed by the Holder) shall be treated for all purposes as the holder of record of such Warrant Shares as of the close of business on such date.

 

 

 

(ii)    In the event of any exercise of the rights represented by this Warrant, certificates for the whole number of shares of Common Stock so purchased shall be delivered to the Holder (or such other person or persons as directed by the Holder) as promptly as is reasonably practicable (but not later than three (3) Business Days) after such exercise at the Company’s expense, and, unless this Warrant has been fully exercised, a new Warrant representing the whole number of Warrant Shares, if any, with respect to which this Warrant shall not then have been exercised shall also be issued to the Holder as soon as reasonably practicable thereafter, (but not later than three (3) Business Days), after such exercise.

 

(b)    Automatic Exercise. If any portion of this Warrant remains unexercised as of either (i) the Expiration Date or (ii) the expiration of the Mandatory Exercise Period and, in either such case, the Fair Market Value (as defined below) of one share of Common Stock as of the such date is greater than the applicable Warrant Price as of the such date, then this Warrant shall be deemed to have been exercised automatically immediately prior to the close of business (i) on the Expiration Date (or, in the event that the Expiration Date is not a Business Day, the immediately preceding Business Day) or (ii) immediately prior to the expiration of the Mandatory Exercise Period, as applicable (the “Automatic Exercise Date”), in the manner provided in Section 1(c) below, and the Holder (or such other person or persons as directed by the Holder) shall be treated for all purposes as the holder of record of such Warrant Shares as of the close of business on such Automatic Exercise Date. This Warrant shall be deemed to be surrendered to the Company on the Automatic Exercise Date by virtue of this Section 1(b) without any action by the Holder. As promptly as is reasonably practicable on or after the Automatic Exercise Date, but in no event prior to the date on which this Warrant is surrendered to the Company at the principal office of the Company, or such other office or agency of the Company as it may reasonably designate by written notice to the Holder, during normal business hours on any Business Day, the Company at its expense shall issue and deliver to the Holder (or such other person or persons as directed by the Holder) a certificate or certificates for the number of Warrant Shares issuable upon such exercise, in accordance with Section 1(c).

 

(c)    Cashless Right to Convert Warrant into Common Stock. In addition to and without limiting the rights of the Holder hereof under the terms of this Warrant, the Holder may elect to receive, without the payment by the Holder of the Warrant Price, Warrant Shares equal to the value of this Warrant or any portion hereof by the surrender of this Warrant (or such portion of this Warrant being so exercised) together with the Net Issue Election Notice annexed hereto as Appendix B duly executed and completed, at the office of the Company, or such other office or agency of the Company as it may reasonably designate by written notice to the Holder, during normal business hours on any Business Day. Thereupon, the Company shall issue to the Holder such number of fully paid, validly issued and nonassessable Warrant Shares, as is computed using the following formula:

 

X= Y(A-B)

A

 

- 2 -

 

where

 

 

X =

the number of shares of Common Stock to be issued to the Holder (or such other person or persons as directed by the Holder) upon such exercise of the rights under this Section 1(c)

 

 

Y =

the total number of shares of Common Stock covered by this Warrant which the Holder has surrendered for cashless exercise

 

 

A =

the “Fair Market Value” of one share of Common Stock on the date that the Holder delivers the Net Issue Election Notice to the Company as provided herein

 

 

B =

the Warrant Price in effect under this Warrant on the date that the Holder delivers the Net Issue Election Notice to the Company as provided herein

 

The “Fair Market Value” of a share of Common Stock as of a particular date (the “Valuation Date”) shall mean the following: (y) if the Common Stock is then listed on a stock exchange or quoted on a quotation system, the closing sale price of one share of Common Stock on such exchange or system on the last trading day prior to the Valuation Date; or (z) if the Common Stock is not then listed on a stock exchange or quoted on a quotation system, the Fair Market Value of one share of Common Stock as of the Valuation Date shall be determined by the Board of Directors of the Company (the “Board”) in its reasonable and good faith judgment. The Board shall respond promptly in writing to an inquiry by the Holder prior to the exercise hereunder as to the Fair Market Value of a share of Common Stock.

 

(d)    Mandatory Exercise. So long as this Warrant shall be outstanding, if the Company proposes to enter into a Mandatory Exercise Transaction (as hereinafter defined), then in any such case, the Company shall cause to be mailed by certified mail to the Holder, at least twenty (20) days prior to the date such proposed Mandatory Exercise Transaction is to be effectuated, a notice containing (i) a brief description of the proposed Mandatory Exercise Transaction; and (ii) the date upon which such proposed Mandatory Exercise Transaction is to take place. The failure to give such notice, however, shall not affect the validity of any proposed Mandatory Exercise Transaction for which the notice was required to be given but shall relieve the Holder of its obligation to exercise the Warrant pursuant to this provision. During the period beginning on the date of Holder’s receipt of such notice and ending on the date which is two (2) days prior to the date upon which such proposed Mandatory Exercise Transaction is to take place, as set forth in the notice (the “Mandatory Exercise Period”), Holder must exercise its right, in accordance with all applicable conditions of exercise set forth in this Warrant, to purchase Warrant Shares which Holder is entitled to purchase hereunder, and if Holder fails to so exercise such right within the Mandatory Exercise Period (unless the Company has failed to give the notice required hereunder), all Warrant Shares for which Holder has not exercised its right to receive hereunder shall expire. For purposes hereof, a “Mandatory Exercise Transaction” shall mean any of the following:

 

(i)    any merger or consolidation of the Company with or into any corporation or other entity that is not a wholly-owned subsidiary of the Company, other than a merger in which the Company or a wholly-owned subsidiary of the Company is the surviving entity; or

 

 

- 3 -

 

(ii)    any sale, exclusive license or other disposition of all or substantially all of the assets of the Company to a person or entity other than a wholly-owned subsidiary of the Company.

 

(e)    Holders Exercise Limitation.

 

(i)    Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the extent that immediately prior to or after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99% (the “Maximum Percentage”) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including the other Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 1(e). For purposes of this Section 1(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934 (the “Exchange Act”), it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act, and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 1(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Reports on Form 8-K or other most recent public filing with the Securities and Exchange Commission, as the case may be, (y) a more recent public announcement by the Company or (z) any other current written notice by the Company setting forth the number of shares of Common Stock outstanding (the “Reported Outstanding Share Number”). For any reason at any time, upon the written request of the Holder, the Company shall within five Business Days confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the Exchange Act), the number of shares so issued by which the Holder’s and the other Attribution Parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage (not in excess of 9.99% of the issued and outstanding shares of Common Stock immediately after giving effect to the issuance of the shares of Common Stock issuable upon exercise of this Warrant) as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the 61st day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(e) to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 1(e) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant.

 

- 4 -

 

(ii)    For purposes of this Section 1(e):

 

a. “Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

 

b. “Attribution Parties” means collectively, the following Persons and entities: (i) any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the date of issuance of this Warrant, directly or indirectly managed or advised by the Holder’s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv) any other Persons whose beneficial ownership of Common Stock would or could be aggregated with the Holder’s and the other Attribution Parties for purposes of Section 13(d) or Section 16 of the Exchange Act. For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage (as defined in Section 1(e)).

 

c. “Group” means a “group” as that term is used in Section 13(d) of the Exchange Act and as defined in Rule 13d-5 thereunder.

 

2.    Reservation of Shares; Stock Fully Paid; Listing. The Company shall keep reserved a sufficient number of shares of the authorized and unissued shares of Common Stock, to provide for the exercise of the rights of purchase represented by this Warrant in compliance with its terms. All Warrant Shares issued upon exercise of this Warrant shall be, at the time of delivery of the certificates for such Warrant Shares upon payment in full of the Exercise Price therefor in accordance with the terms of this Warrant (or proper exercise of the cashless exercise rights contained in Section 3(c) hereof), duly authorized, validly issued, fully paid and non-assessable shares of Common Stock of the Company. The Company shall during all times prior to the Expiration Date when the shares of Common Stock issuable upon the exercise of this Warrant are authorized for quotation or listing on a stock exchange or quotation system, keep the shares of Common Stock issuable upon the exercise of this Warrant authorized for quotation such exchange or system, as the case may be.

 

3.    Adjustments and Distributions. The number and kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows:

 

(a)    Dividends and Distributions. If the Company shall at any time or from time to time while this Warrant is outstanding, pay a dividend or make a distribution on its Common Stock in shares of Common Stock, subdivide its outstanding shares of Common Stock into a greater number of shares or combine its outstanding shares of Common Stock into a smaller number of shares, then the number of Warrant Shares purchasable upon exercise of this Warrant and the Warrant Price in effect immediately prior to the date upon which such change shall become effective shall be proportionally adjusted by the Company so that the Holder thereafter exercising this Warrant shall be entitled to receive the number of shares of Common Stock or other capital stock which the Holder would have received if this Warrant had been exercised immediately prior to such event (taking into account such event) upon payment of a Warrant Price that has been proportionally adjusted to reflect such event. Such adjustments shall be made successively whenever any event listed above shall occur.

 

- 5 -

 

(b)    Reorganization. If any recapitalization, reclassification or reorganization of the capital stock of the Company (other than a change in par value or a subdivision or combination as provided for in Section 3(a) above) shall be effected in such a manner (including, without limitation, in connection with a consolidation or merger in which the Company is the continuing corporation), that holders of Common Stock shall be entitled to receive stock, securities, or other assets or property (a “Reorganization”), then, as a condition of such Reorganization, lawful and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter have the right to purchase and receive (in lieu of the shares of the Common Stock of the Company immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby) such shares of stock, securities or other assets or property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such Common Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby. In the event of any Reorganization, appropriate provision shall be made by the Company with respect to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation, provisions for adjustments of the Warrant Price and of the number of Warrant Shares) shall thereafter be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof. The provisions of this Section 3(b) shall similarly apply to successive Reorganizations.

 

(c)    Mergers and other Transactions. If any consolidation or merger of the Company with another entity in which the Company is not the survivor, or sale, transfer, exclusive license or other disposition of all or substantially all of the Company’s assets to another entity shall be effected, then, as a condition of such consolidation, merger, sale, transfer, exclusive license or other disposition, lawful and adequate provision shall be made whereby the Holder shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions herein specified and in lieu of the Warrant Shares immediately theretofore issuable upon exercise of this Warrant, such shares of stock, securities or assets as would have been issuable or payable with respect to or in exchange for a number of Warrant Shares equal to the number of Warrant Shares immediately theretofore issuable upon exercise of this Warrant, had such consolidation, merger, sale, transfer, exclusive license or other disposition not taken place, and in any such case appropriate provision shall be made with respect to the rights and interests of each Holder to the end that the provisions hereof (including, without limitation, provision for adjustment of the Warrant Price and of the number of Warrant Shares) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any shares of stock, securities or properties thereafter deliverable upon the exercise thereof. The Company shall not effect any such consolidation, merger, sale, transfer or other disposition unless prior to or simultaneously with the consummation thereof the successor entity (if other than the Company) resulting from such consolidation or merger, or the entity purchasing or otherwise acquiring such assets or other appropriate entity shall assume the obligation to deliver to the Holder such shares of stock, securities or assets as, in accordance with the foregoing provisions, such Holder may be entitled to purchase, and the other obligations under this Warrant. The provisions of this Section 3(c) shall similarly apply to successive consolidations, mergers, sales, transfers or other dispositions.

 

- 6 -

 

(d)    Price and Payment. In case the Company shall fix a payment date for the making of a distribution to all holders of Common Stock of evidences of indebtedness or assets (other than dividends or distributions referred to in Section 3(a) hereof), or subscription rights or warrants, the Warrant Price to be in effect after such payment date shall be determined by multiplying the Warrant Price in effect immediately prior to such payment date by a fraction, the numerator of which shall be the total number of shares of Common Stock outstanding multiplied by the Fair Market Value per share of Common Stock immediately prior to such payment date, less the fair market value (as determined by the Board in good faith) of said assets or evidences of indebtedness so distributed, or of such subscription rights or warrants, and the denominator of which shall be the total number of shares of Common Stock outstanding multiplied by such Fair Market Value per share of Common Stock immediately prior to such payment date. Such adjustment shall be made successively whenever such a payment date is fixed.

 

(i)    In the event that any dividend or distribution for which this Section 3(d) would require an adjustment is not so paid or made, the Warrant Price shall be adjusted to be the Warrant Price which would then be in effect if such dividend or distribution had not been declared.

 

(ii)    In the event that the Company implements a new shareholder rights plan, such rights plan shall provide that upon exercise of this Warrant the Holder will receive, in addition to the Common Stock issuable upon such exercise, the rights issued under such rights plan (as if the Holder had exercised this Warrant prior to implementing the rights plan and notwithstanding the occurrence of an event causing such rights to separate from the Common Stock at or prior to the time of exercise). Any distribution of rights or warrants pursuant to a shareholder rights plan complying with the requirements set forth in the immediately preceding sentence of this paragraph shall not constitute a distribution of rights or warrants for the purposes of this Section 3(d).

 

(e)    Effective Date. An adjustment pursuant to this Section 3 shall become effective immediately after the payment date in the case of each dividend or distribution and immediately after the effective date of each other event which requires an adjustment.

 

(f)    Other Shares. In the event that, as a result of an adjustment made pursuant to this Section 3, the Holder shall become entitled to receive any shares of capital stock of the Company other than shares of Common Stock, the number of such other shares so receivable upon exercise of this Warrant shall be subject thereafter to adjustment from time to time in a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Warrant Shares contained in this Warrant.

 

(g)    Notice of Adjustments. With each adjustment pursuant to this Section 3, the Company shall deliver a certificate signed by its chief financial or executive officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and the number of Warrant Shares purchasable hereunder after giving effect to such adjustment, which shall be mailed by first class mail, postage prepaid to the Holder.

 

- 7 -

 

4.    Transfer Taxes. The Company will pay any documentary stamp taxes attributable to the initial issuance of Warrant Shares issuable upon the exercise of the Warrant; provided, however, that the Company shall not be required to pay any tax or taxes which may be payable in respect of any transfer involved in the issuance or delivery of any certificates for Warrant Shares in a name other than that of the registered holder of this Warrant in respect of which such shares are issued, and in such case, the Company shall not be required to issue or deliver any certificate for Warrant Shares or any Warrant until the person requesting the same has paid to the Company the amount of such tax or has established to the Company’s reasonable satisfaction that such tax has been paid.

 

5.    Mutilated or Missing Warrants. In case this Warrant shall be mutilated, lost, stolen, or destroyed, the Company shall issue in exchange and substitution of and upon cancellation of the mutilated Warrant, or in lieu of and substitution for the Warrant lost, stolen or destroyed, a new Warrant of like tenor and for the purchase of a like number of Warrant Shares, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction of the Warrant, and with respect to a lost, stolen or destroyed Warrant, reasonable indemnity or bond with respect thereto, if requested by the Company.

 

6.    Fractional Shares. No fractional shares of Common Stock shall be issued in connection with any exercise or cashless exercise hereunder, and in lieu of any such fractional shares the Company shall make a cash payment therefor to the Holder (or such other person or persons as directed by the Holder) based on the Fair Market Value of a share of Common Stock on the date of exercise or cashless exercise of this Warrant.

 

7.    Compliance with Securities Act and Legends. The Holder, by acceptance hereof, agrees that this Warrant and the shares of Common Stock to be issued upon exercise hereof, are being acquired for investment and that such Holder will not offer, sell or otherwise dispose of this Warrant, or any shares of Common Stock to be issued upon exercise hereof except under circumstances which will not result in a violation of the Securities Act of 1933, as amended, or the rules and regulations promulgated thereunder, as amended (the “Act”), or any state’s securities laws. Upon exercise of this Warrant, the Holder shall confirm in writing, by executing the form attached as Schedule 1 to Appendix A hereto, that the shares of Common Stock so purchased are being acquired for investment and not with a view toward distribution or resale. All shares of Common Stock issued upon exercise of this Warrant (unless registered under the Act) shall be stamped or imprinted with a legend as follows:

 

THIS SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING THESE SECURITIES UNDER THE ACT AND ANY OTHER APPLICABLE SECURITIES LAWS, OR (2) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

- 8 -

 

8.    Rights as Stockholders. Except as expressly provided in this Warrant, no Holder, as such, shall be entitled to vote or receive dividends or be deemed the holder of Common Stock or any other securities of the Company which may at any time be issuable on the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the Holder, as such, any of the rights of a stockholder of the Company or any right to vote for the election of the directors or upon any matter submitted to stockholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or otherwise, until this Warrant shall have been exercised and the Warrant Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.

 

9.    Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the Company and the then current Holder, and such change, waiver, discharge or termination shall be binding on all future Holders.

 

10.    Notices. Unless otherwise specifically provided herein, all communications under this Warrant shall be in writing and shall be deemed to have been duly given (a) on the date personally delivered to the party to whom notice is to be given, (b) on the day of transmission if sent by facsimile transmission to a number provided to a party specifically for such purposes and the sending party receives confirmation of the completion of such transmission, (c) on the Business Day after delivery to Federal Express or similar overnight courier which utilizes a written form of receipt, or (d) on the fifth day after mailing, if mailed to the party to whom notice is to be given, by first class mail, registered or certified, postage prepaid, and properly addressed, return receipt requested, to each such Holder at its address as shown on the books of the Company or to the Company at the address indicated therefor on the signature page of this Warrant. Any party hereto may change its address for purposes of this Section 9 by giving the other party written notice of the new address in the manner set forth herein.

 

11.    Descriptive Headings. The descriptive headings contained in this Warrant are inserted for convenience only and do not constitute a part of this Warrant.

 

12.    Governing Law. The validity, interpretation and performance of this Warrant shall be governed by, and construed in accordance with, the laws of the State of Delaware applicable to contracts made and to be performed entirely within such State, regardless of the law that might be applied under principles of conflicts of law. The Company and, by accepting this Warrant, the Holder, each irrevocably submits to the exclusive jurisdiction of the courts of the State of Delaware and the United States District Court for the District of Delaware for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Warrant and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Warrant. The Company and, by accepting this Warrant, the Holder, each irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. The Company and, by accepting this Warrant, the Holder, each irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum.

 

- 9 -

 

13.    Acceptance. Receipt of this Warrant by the Holder hereof shall constitute acceptance of and agreement to the foregoing terms and conditions.

 

14.    No Impairment of Rights. The Company will not, by amendment of its Certificate of Incorporation or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against material impairment.

 

15.    Assignment. A Holder may transfer its rights hereunder, in whole or in part, to any other person (other than a competitor of the Company, as determined by the Board in good faith; provided, however, ________________ shall be deemed not to be a competitor), provided that written notice is given to the Company of any such transfer and such transfer is in accordance with applicable law. Upon receipt by the Company of notice by a Holder of a transfer of any portion of this Warrant, the Company shall promptly deliver to a transferee a Warrant in the form hereof exercisable for the number of Warrant Shares the right of which to purchase has been transferred. In addition to, and not in limitation of, the foregoing, a Holder that is a corporation, a partnership or a limited liability company, may distribute any portion of a warrant to its respective shareholders, partners or members.

 

* * *

 

- 10 -

 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed on its behalf by one of its officers thereunto duly authorized on the date set forth above.

 

 

CERVOMED INC.

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

John Alam, President & CEO

 

 

 

[Signature Page to Access Common Stock Warrant]


 

 

APPENDIX A

 

Notice of Exercise

 

To: CervoMed Inc.

 

1.         The undersigned hereby irrevocably elects to purchase [_____] shares of Common Stock of CervoMed Inc. pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full, by cash, certified check/wire transfer/surrender of the originally executed Warrant.

 

2.         Please issue a certificate or certificates representing said shares in the name of the undersigned or in such other name or names as are specified below:

 

 


 


(Name)

 

 


(Address)

 

   (Signature)
   (Date)

 

3.         Please issue a new Warrant of equivalent form and tenor for the unexercised portion of the attached Warrant in the name of the undersigned or in such other name as is specified below:

 

                                                                                                                                                                 

Date:                                                                                                                                                      

 

(Warrantholder)                                                                                                                                     

 

Name: (Print)                                                                                                                                         

 

By:                                                                                                                                                         

 

 

 

 

Schedule 1

 

INVESTMENT REPRESENTATION STATEMENT

 

Purchaser:     
Company: CervoMed Inc.  
Security: Common Stock  
Amount:    
Date:    

   

In connection with the purchase of the above-listed securities (the “Securities”), the undersigned (the “Purchaser”) represents to the Company as follows:

 

(a)         The Purchaser is aware of the Company’s business affairs and financial condition, and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities. The Purchaser is purchasing the Securities for its own account for investment purposes only and not with a view to, or for the resale in connection with, any “distribution” thereof for purposes of the Securities Act of 1933, as amended (the “Act”).

 

(b)         The Purchaser understands that the Securities have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Purchaser’s investment intent as expressed herein. In this connection, the Purchaser understands that, in the view of the Securities and Exchange Commission (“SEC”), the statutory basis for such exemption may be unavailable if the Purchaser’s representation was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified under applicable tax laws, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one year or any other fixed period in the future.

 

(c)         The Purchaser further understands that the Securities must be held indefinitely unless subsequently registered under the Act or unless an exemption from registration is otherwise available. In addition, the Purchaser understands that the certificate evidencing the Securities will be imprinted with the legend referred to in the Warrant under which the Securities are being purchased.

 

(d)         The Purchaser is aware of the provisions of Rule 144 and 144A, promulgated under the Act, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate of such issuer), in a non-public offering subject to the satisfaction of certain conditions, if applicable, including, among other things: The availability of certain public information about the Company, the resale occurring not less than one (1) year after the party has purchased and paid for the securities to be sold; the sale being made through a broker in an unsolicited “broker’s transaction” or in transactions directly with a market maker (as said term is defined under the Securities Exchange Act of 1934, as amended) and the amount of securities being sold during any three-month period not exceeding the specified limitations stated therein.

 

 

 

(e)         The Purchaser further understands that at the time it wishes to sell the Securities there may be no public market upon which to make such a sale, and that, even if such a public market then exists, the Company may not be satisfying the current public information requirements of Rule 144 and 144A, and that, in such event, the Purchaser may be precluded from selling the Securities under Rule 144 and 144A even if the one-year minimum holding period had been satisfied.

 

(f)         The Purchaser further understands that in the event all of the requirements of Rule 144 and 144A are not satisfied, registration under the Act, compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rule 144 is not exclusive, the Staff of the SEC has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rule 144 will have a substantial burden or proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk.

 

 

 

Purchaser:                                                                                  

 

 

 

 

APPENDIX B

 

Net Issue Election Notice

 

To:

[                                                            ]

 

Date:

[                                                            ]

 

The undersigned hereby elects under Section [__] of this Warrant to surrender the right to purchase [______________] shares of Common Stock pursuant to this Warrant and hereby requests the issuance of [______________] shares of Common Stock. The certificate(s) for the shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated below.

 

 


Signature

 

 


Name for Registration

 

 


Mailing Address

 

 

 
EX-4.3 8 ex_562003.htm EXHIBIT 4.3 ex_562003.htm
 

Exhibit 4.3

 

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY.

 

PRE-FUNDED COMMON STOCK PURCHASE WARRANT

 

CERVOMED INC.

 

Warrant Shares: [•]

 

Date of Issuance: [•], 2023 (such date, the “Issue Date”)
Warrant No.: PF-[•]

 

THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or after the Issue Date, to subscribe for and purchase from CervoMed Inc., a Delaware corporation (the “Company”), up to [•] shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal $0.001 (as adjusted from time to time as provided in Section 3 herein, the “Exercise Price”). This Warrant is one of the Pre-Funded Common Stock Purchase Warrants issued in connection with the transactions contemplated by (i) that certain Agreement and Plan of Merger, dated as of March 30, 2023, by and between Diffusion Pharmaceuticals Inc., Dawn Merger Sub Inc. and EIP Pharma, Inc. (“EIP”), and (ii) [•].

 

Section 1.

Definitions. For purposes of this Warrant, the following terms shall have the following meanings:

 

 

(a)

Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”).

 

 

(b)

Attribution Parties” means, collectively, the following Persons and entities: (i) any investment vehicle, including, any funds, feeder funds or managed accounts, currently, or from time to time after the Issue Date, directly or indirectly managed or advised by the Holder’s investment manager or any of its Affiliates or principals, (ii) any direct or indirect Affiliates of the Holder or any of the foregoing, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any of the foregoing and (iv) any other Persons whose beneficial ownership of Common Stock would or could be aggregated with the Holder’s and the other Attribution Parties for purposes of Section 13(d) or Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage (as defined in Section 2(d)).

 

 

(c)

Bloomberg” means Bloomberg Financial Markets.

 

 

(d)

Business Day” means any day except any Saturday, any Sunday, any day that is a federal legal holiday in the United States or any day on which the Trading Market is authorized or required by law or other governmental action to close.

 

 

(e)

Group” means a “group” as that term is used in Section 13(d) of the Exchange Act and as defined in Rule 13d-5 thereunder.

 

1

 

 

(f)

Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

 

 

(g)

Trading Day” means any day on which the Common Stock is traded on the Trading Market.

 

 

(h)

Trading Market” means the principal securities exchange or securities market, including an over-the-counter market, on which the Common Stock is then traded in the United States.

 

 

(i)

Weighted Average Price” means, for any security as of any date, the dollar volume-weighted average price for such security on the Trading Market during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg through its “Volume at Price” function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the “pink sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Weighted Average Price cannot be calculated for such security on such date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Error! Reference source not found. with the term “Weighted Average Price” being substituted for the term “Exercise Price.” All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during such period.

 

Section 2.

Exercise.

 

 

(a)

Exercise of Warrant. Subject to the terms and conditions hereof, the purchase rights represented by this Warrant may be exercised, in whole or in part, at any time or times on or after the Issue Date by delivery (whether via facsimile or otherwise) to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed copy of the Notice of Exercise form annexed hereto (the “Notice of Exercise”) and by payment to the Company of an amount equal to the aggregate Exercise Price of the Warrant Shares thereby purchased by wire transfer (or by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined below)). No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required. The Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder, and the Warrant has been exercised in full, in which case the Holder shall surrender this Warrant to the Company for cancellation within three Trading Days after the date the Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

2

 

 

(b)

Mechanics of Exercise.

 

 

(i)

Delivery of Warrant Shares Upon Exercise. Certificates for shares purchased hereunder shall be transmitted to the Holder by crediting the account of the Holder’s prime broker with The Depository Trust Company (“DTC”) through its Deposit/Withdrawal at Custodian (“DWAC”) system if the Company is then a participant in such system and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by the date that is two Trading Days after the receipt by the Company of the Notice of Exercise (provided that payment of the Exercise Price (or notification of Cashless Exercise, if applicable) has then been received by the Company) (such date, the “Warrant Share Delivery Date”). This Warrant shall be deemed to have been exercised upon proper delivery of the Notice of Exercise and payment of the Exercise Price (or notification of Cashless Exercise). The Warrant Shares shall be deemed to have been issued, and the Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised. The Company shall use its reasonable best efforts to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.

 

 

(ii)

Delivery of New Warrant Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

 

(iii)

Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(b)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than a failure caused by incorrect or incomplete information provided by the Holder to the Company), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall either (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, or (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of this Warrant with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence, the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof.

 

 

(iv)

No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round (up or down) to the nearest whole share.

 

3

 

 

(v)

Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

 

 

(vi)

Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant pursuant to the terms hereof.

 

 

(c)

Cashless Exercise. Notwithstanding anything contained herein to the contrary, the Holder may exercise this Warrant, whether in whole or in part, and in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Exercise Price, by effecting a cashless exercise of this Warrant pursuant to which the Holder shall receive upon such cashless exercise the “Net Number” of Warrant Shares determined according to the following formula (a “Cashless Exercise”):

 

Net Number =            (A x B) - (A x C)   
                                                              B

 

For purposes of the foregoing formula:

 

A =         the total number of shares of Common Stock with respect to which this Warrant is then being exercised.

 

B =         the Weighted Average Price of the shares of Common Stock on the date immediately preceding the date of the Notice of Exercise.

 

C =         the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.

 

If Warrant Shares are issued in such a Cashless Exercise, the Company acknowledges and agrees that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrant being exercised, and the holding period of the Warrant being exercised may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).

 

4

 

 

(d)

Holders Exercise Limitations. Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and the Holder shall not have the right to exercise any portion of this Warrant, pursuant to the terms and conditions of this Warrant and any such exercise shall be null and void and treated as if never made, to the extent that immediately prior to or after giving effect to such exercise, the Holder together with the other Attribution Parties collectively would beneficially own in excess of 9.99% (or, at the election of the Holder prior to the issuance of the Warrant, 4.99%) (the “Maximum Percentage”) of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by the Holder and the other Attribution Parties shall include the number of shares of Common Stock held by the Holder and all other Attribution Parties plus the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (A) exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of the other Attribution Parties and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any convertible notes or convertible preferred stock or warrants, including the other Warrants) beneficially owned by the Holder or any other Attribution Party subject to a limitation on conversion or exercise analogous to the limitation contained in this Section 2(d). For purposes of this Section 2(d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act, and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(d) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock the Holder may acquire upon the exercise of this Warrant without exceeding the Maximum Percentage, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Reports on Form 8-K or other most recent public filing with the Securities and Exchange Commission, as the case may be, (y) a more recent public announcement by the Company or (z) any other current written notice by the Company setting forth the number of shares of Common Stock outstanding (the “Reported Outstanding Share Number”). For any reason at any time, upon the written request of the Holder, the Company shall within five Business Days confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and any other Attribution Party since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder and the other Attribution Parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the Exchange Act), the number of shares so issued by which the Holder’s and the other Attribution Parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and shall be cancelled ab initio, and the Holder shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. Upon delivery of a written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage (not in excess of 9.99% of the issued and outstanding shares of Common Stock immediately after giving effect to the issuance of the shares of Common Stock issuable upon exercise of this Warrant) as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective until the 61st day after such notice is delivered to the Company and (ii) any such increase or decrease will apply only to the Holder and the other Attribution Parties and not to any other holder of Warrants that is not an Attribution Party of the Holder. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act. No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(d) to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section 2(d) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant. Notwithstanding the foregoing, at any time following notice of a Fundamental Transaction under Section 3(d) with respect to a Section 3(d) Fundamental Transaction, the Holder may waive and/or change the beneficial ownership limitation effective immediately upon written notice to the Company and may reinstitute a beneficial ownership limitation at any time thereafter effective immediately upon written notice to the Company.

 

5

 

 

(e)

Notwithstanding anything to the contrary contained in any Section herein (including Section 2(d), the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties, to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and Attribution Parties to exceed 9.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Section 2(e), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and Attribution Parties.

 

Section 3.

Certain Adjustments.

 

 

(a)

Subdivision or Combination of Common Stock. During such time as this Warrant is outstanding, if the Company subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Subscription Date combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 3(a) shall become effective at the close of business on the date the subdivision or combination becomes effective.

 

 

(b)

Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if during such time as this Warrant is outstanding the Company grants, issues or sells any rights to purchase stock, warrants, securities or other property, in each case pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, Section 2(d) hereof) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage).

 

 

(c)

Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, Section 2(d) hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage).

 

6

 

 

(d)

Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions (which, for the avoidance of doubt, shall not include a license or other agreement granting rights to intellectual property), (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(d) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (together, the “Alternate Consideration”), if any, receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(d) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Any such payment of such amount of such Alternative Consideration shall be made in the same form of consideration (whether securities, cash or property) as is given to the holders of Common Stock in such Fundamental Transaction, and if multiple forms of consideration are given, the consideration shall be paid to the Holder in the same proportion as such consideration is paid to the holders of Common Stock. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this Section 3(f) and insuring that this Warrant (or any such replacement security) will be similarly adjusted upon any subsequent Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such adjustments to the number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Notwithstanding the foregoing, and without limiting Section 2(d) hereof, the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section 3(d) to permit a Fundamental Transaction without the assumption of this Warrant.

 

 

(e)

Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest whole share, as the case may be. For purposes of this Section 3, any calculation of the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall not include treasury shares, if any.

 

 

(f)

Par Value. Notwithstanding anything to the contrary in this Warrant, in no event shall the Exercise Price be reduced below the par value of the Company’s Common Stock.

 

Section 4.

Transfer of Warrant.

 

 

(a)

Transferability. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company (or other designated agent), together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

 

(b)

New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company (or other designated agent), together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date set forth on the first page of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

7

 

 

(c)

Warrant Register. The Company shall initially serve as warrant agent under this Warrant. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. Upon 30 days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

 

Section 5.

Miscellaneous.

 

 

(a)

No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2.

 

 

(b)

Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to them of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

 

(c)

Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

 

 

(d)

Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant (without regard to any limitations on exercise contained herein). The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, in each case to avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use its reasonable best efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

8

 

 

(e)

Governing Law. This Warrant shall be governed by, and construed in accordance with, the laws of the State of Delaware without giving effect to the conflicts of law principles thereof.

 

 

(f)

Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies.

 

 

(g)

Notices.

 

 

(i)

Notice Procedures. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered via email or facsimile at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via email or facsimile on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or by International Federal Express, (d) the third Trading Day following the date of mailing if sent by first-class registered or certified mail domestic, or (e) upon actual receipt by the party to whom such notice is required to be given. The addresses for such communications shall be:

 

If to the Company:

 

CervoMed Inc.
20 Park Plaza, Suite 424
Boston, Massachusetts 02116
Attention: Chief Executive Officer
Email: jalam@eippharma.com

 

With copy to:

 

Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C.
One Financial Center
Boston, MA 02111
Attention: William C. Hicks

Scott M. Stanton

Jason S. McCaffrey

Email: wchicks@mintz.com

smstanton@mintz.com

jsmccaffrey@mintz.com

 

If to the Holder:

 

To the address, email address or facsimile number set forth in the Warrant Register, or as otherwise provided by the Holder to the Company in accordance with this Section 5(g)(i).

 

 

(ii)

Adjustment to Exercise Price. Whenever the Exercise Price or number of Warrant Shares is adjusted pursuant to any provision of Section 3, the Company shall promptly provide the Holder a notice setting forth the Exercise Price and number of Warrant Shares after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

 

9

 

 

(iii)

Notice to Allow Exercise by the Holder. After the Issue Date, if (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company (which, for the avoidance of doubt, shall not include a license or other agreement granting rights to intellectual property), or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register, at least ten calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. Holder agrees to maintain any information disclosed pursuant to this Section 5(g)(iii) in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the Company’s securities following receipt any such information.

 

 

(h)

Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

 

 

(i)

Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant to Section 2(c) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

 

 

(j)

Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of the Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

 

(k)

Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

 

(l)

Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

10

 

 

(m)

Confidentiality. The Holder agrees to keep confidential any proprietary information relating to the Company delivered by the Company hereunder; provided that nothing herein shall prevent the Holder from disclosing such information: (i) to any holder of Warrants or Warrant Shares, (ii) to any Affiliate of any holder of Warrants or Warrant Shares or any actual or potential transferee of the rights or obligations hereunder that agrees to be bound by this Section 5(m), (iii) upon order, subpoena, or other process of any court or administrative agency or otherwise required by law, (iv) upon the request or demand of any regulatory agency or authority having jurisdiction over such party, (v) which has been publicly disclosed without breach of any obligation to the Company, (vi) which has been obtained from any Person that is not a party hereto or an Affiliate of any such party without any breach of any obligation to the Company, (vii) in connection with the exercise of any remedy, or the resolution of any dispute hereunder, (viii) to the legal counsel or certified public accountants for any holder of Warrants or Warrant Shares, or (ix) as otherwise expressly contemplated by this Warrant. Notwithstanding the foregoing, the Company shall not provide material, non-public information or confidential or proprietary information to the Holder without such Holder’s written consent.

 

 

(n)

Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

[Remainder of page intentionally left blank]

 

11

 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

 

CERVOMED INC.

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

Name:

John Alam

 

 

Title:

Chief Executive Officer

 

         

[Signature Page to Pre-Funded Warrant]


 

NOTICE OF EXERCISE

 

To: CervoMed Inc.

 

(1)

The undersigned holder of Warrant No. PF-  hereby elects to purchase Warrant Shares of the Company pursuant to the terms of the attached  Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)

Payment shall take the form of (check applicable box):

 

 

Cash Exercise: lawful money of the United States; or

 

 

Cashless Exercise: the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in Section 2(c).

 

(3)

Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

 

(4)

By its delivery of this Notice of Exercise, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 2(d) of the Warrant to which this notice relates.

 

(5)

Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

 


 

 


 

 


 

 

 

 

 

    [Name of Investing Entity]

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

 

 

 

Name: 

 

       
    Title:   
       
    Date:   

 

 

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute
this form and supply required information.
Do not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED, [       ] all of or [       ] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to:

 

 


 

whose address is:   

 

 
     
     
     
     

 

 

Dated:

 

 

 

Holder’s Signature:      
   
Holder’s Address:     
   
   
   
   

 

 

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever.

 

***

 

 

 
EX-10.9 9 ex_562004.htm EXHIBIT 10.9 ex_562004.htm

Exhibit 10.9

 

INDEMNIFICATION AGREEMENT

 

This Indemnification Agreement (the “Agreement”) is made and entered into this ___ day of ______________, by and between CervoMed Inc. (f/k/a Diffusion Pharmaceuticals Inc.), a Delaware corporation (the “Company,” which term shall include, where appropriate, any Entity (as hereinafter defined) controlled directly or indirectly by the Company), and ___________________________ (the “Indemnitee”).

 

WHEREAS, it is essential to the Company that it be able to retain and attract as directors and officers the most capable persons available;

 

WHEREAS, increased corporate litigation has subjected directors and officers to litigation risks and expenses, and the limitations on the availability of directors and officers liability insurance have made it increasingly difficult for the Company to attract and retain such persons;

 

WHEREAS, the Company’s Certificate of Incorporation, as amended, and Bylaws (the “Certificate” and the “Bylaws,” respectively), provide that the Company is authorized to indemnify its directors and officers to the fullest extent permissible by applicable law and permit it to make other indemnification arrangements and agreements;

 

WHEREAS, the Company desires to provide Indemnitee with specific contractual assurance of Indemnitee’s rights to full indemnification against litigation risks and expenses (regardless, among other things, of any amendment to or revocation of the Certificate or Bylaws or any change in the ownership of the Company or the composition of its board of directors (the “Board of Directors”));

 

WHEREAS, the Company intends that this Agreement provide Indemnitee with greater protection than that which is provided by the Certificate and Bylaws; and

 

WHEREAS, Indemnitee is relying upon the rights afforded under this Agreement in becoming or continuing as a director and/or officer of the Company.

 

NOW, THEREFORE, in consideration of the promises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

 

1.    Definitions.

 

(a)    Corporate Status” describes the status of a person who is serving or has served (i) as a director and/or officer of the Company, (ii) in any capacity with respect to any employee benefit plan of the Company or (at the request of the Company) any employee benefit plan of any other Entity, or (iii) as a director and/or officer of any other Entity at the request of the Company. For purposes of subsections (ii) and (iii) of this Section 1(a), if Indemnitee is serving or has served as a director and/or officer of a Subsidiary (as defined below), or in any capacity with respect to any employee benefit plan of a Subsidiary, Indemnitee shall be deemed to be serving at the request of the Company. If Indemnitee is an employee of the Company, Corporate Status shall not include actions taken by Indemnitee in any capacity other than as a director and/or officer or as a representative of any employee benefit plan.

 

 

 

 

(b)    Entity” shall mean any corporation, partnership, limited liability company, joint venture, trust, foundation, association, organization or other legal entity.

 

(c)    Expenses” shall mean all fees, costs and expenses incurred by Indemnitee in connection with any Proceeding (as defined below), including, without limitation, reasonable attorneys’ fees, disbursements and retainers (including, without limitation, any such fees, disbursements and retainers incurred by Indemnitee pursuant to Sections 11 and 12(c) of this Agreement), fees and disbursements of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), court costs, transcript costs, fees of experts, travel expenses, duplicating, printing and binding costs, telephone and fax transmission charges, postage, delivery services, secretarial services and other disbursements and expenses.

 

(d)    Indemnifiable Expenses,” “Indemnifiable Liabilities” and “Indemnifiable Amounts” shall have the meanings ascribed to those terms in Section 3(a) below.

 

(e)    Liabilities” shall mean judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement.

 

(f)    Proceeding” shall mean any threatened, pending or completed claim, action, suit, arbitration, alternate dispute resolution process, investigation, administrative hearing, appeal or any other proceeding, whether civil, criminal, administrative, arbitrative or investigative, whether formal or informal, including a proceeding initiated by Indemnitee pursuant to Section 11 of this Agreement to enforce Indemnitee’s rights hereunder.

 

(g)    Subsidiary” shall mean any corporation, partnership, limited liability company, joint venture, trust or other Entity of which the Company owns (either directly or through or together with another Subsidiary of the Company) either (i) a general partner, managing member or other similar interest or (ii) (A) 50% or more of the voting power of the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other Entity or (B) 50% or more of the outstanding voting capital stock or other voting equity interests of such corporation, partnership, limited liability company, joint venture or other Entity.

 

(h)    to the fullest extent permissible by applicable law” shall include, but not be limited to: (i) the fullest extent permitted by the provisions of the General Corporation Law of the State of Delaware (the “DGCL”) that authorize or contemplate additional or supplementary indemnification by agreement, or the corresponding provisions of any amendment to or replacement of the DGCL or such provisions thereof; and (ii) the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its directors and/or officers.

 

2

 

2.    Services of Indemnitee. In consideration of the Company’s covenants and commitments hereunder, Indemnitee agrees to serve or continue to serve as a director and/or officer of the Company. However, this Agreement shall not impose any obligation on Indemnitee or the Company to continue Indemnitee’s service to the Company beyond any period otherwise required by law or by other agreements or commitments of the parties, if any.

 

3.    Agreement to Indemnify. The Company agrees to hold harmless and indemnify Indemnitee to the fullest extent permissible by applicable law as follows:

 

(a)    Proceedings. Subject to the exceptions contained in Section 4(a) below, if Indemnitee was or is a party or is threatened to be made a party to any Proceeding by reason of Indemnitee’s Corporate Status, Indemnitee shall be indemnified by the Company against all Expenses and Liabilities actually and reasonably incurred or paid by Indemnitee in connection with such Proceeding (referred to herein as “Indemnifiable Expenses” and “Indemnifiable Liabilities,” respectively, and collectively as “Indemnifiable Amounts”).

 

(b)    Conclusive Presumption Regarding Standard of Care. In making any determination required to be made under Delaware law with respect to entitlement to indemnification hereunder, the person, persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee submitted a request therefor in accordance with Section 5 of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making by any person, persons or Entity of any determination contrary to that presumption.

 

4.    Exceptions to Indemnification. Subject to Section 20 below, Indemnitee shall be entitled to indemnification under Section 3(a) above in all circumstances and with respect to each and every specific claim, issue or matter involved in the Proceeding out of which Indemnitee’s claim for indemnification has arisen to the fullest extent permissible by applicable law, except as follows:

 

(a)    Proceedings. If indemnification is requested under Section 3(a) and it has been finally adjudicated by a court of competent jurisdiction that, in connection with such specific claim, issue or matter, Indemnitee failed to act (i) in good faith and (ii) in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, or, with respect to any criminal Proceeding, Indemnitee had reasonable cause to believe that Indemnitee’s conduct was unlawful, Indemnitee shall not be entitled to payment of Indemnifiable Amounts hereunder to the extent that they arise out of such claim, issue or matter.

 

(b)    Insurance Proceeds. To the extent payment is actually made to the Indemnitee under a valid and collectible insurance policy maintained at the expense of the Company in respect of Indemnifiable Amounts in connection with such specific claim, issue or matter, Indemnitee shall not be entitled to payment of Indemnifiable Amounts hereunder except in respect of any excess of such Indemnifiable Amounts beyond the amount of payment under such insurance.

 

3

 

5.    Procedure for Payment of Indemnifiable Amounts. Indemnitee shall submit to the Company a written request specifying the Indemnifiable Amounts for which Indemnitee seeks payment under Section 3 of this Agreement and the basis for the claim. The Company shall pay such Indemnifiable Amounts to Indemnitee promptly, but in no event later than thirty (30) calendar days after receipt of such request. At the request of the Company, Indemnitee shall furnish such documentation and information as are reasonably available to Indemnitee and necessary to establish that Indemnitee is entitled to indemnification hereunder.

 

6.    Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provision of this Agreement, and without limiting any such provision, to the extent that Indemnitee is, by reason of Indemnitee’s Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, Indemnitee shall be indemnified to the fullest extent permissible by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify to the fullest extent permissible by applicable law Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Agreement, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, by reason of settlement, judgment, order or otherwise, shall be deemed to be a successful result as to such claim, issue or matter.

 

7.    Effect of Certain Resolutions. Neither the settlement nor termination of any Proceeding nor the failure of the Company to award indemnification or to determine that indemnification is payable shall create a presumption that Indemnitee is not entitled to indemnification hereunder. In addition, the termination of any Proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, had reasonable cause to believe that Indemnitee’s action was unlawful.

 

8.    Agreement to Advance Expenses; Undertaking. The Company shall advance to the fullest extent permissible by applicable law all Expenses actually and reasonably incurred by or on behalf of Indemnitee in connection with any Proceeding in which Indemnitee is involved by reason of such Indemnitee’s Corporate Status within thirty (30) calendar days after the receipt by the Company of a written statement from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s ability to repay the expenses and without regard to Indemnitee’s ultimate entitlement to indemnification under the other provisions of this Agreement. To the extent required by Delaware law, Indemnitee hereby undertakes to repay any and all of the amount of Indemnifiable Expenses paid to Indemnitee if it is finally determined by a court of competent jurisdiction that Indemnitee is not entitled under this Agreement to indemnification with respect to such Expenses. This undertaking is an unlimited general obligation of Indemnitee.

 

9.    Procedure for Advance Payment of Expenses. Indemnitee shall submit to the Company a written request specifying the Indemnifiable Expenses for which Indemnitee seeks an advancement under Section 8 of this Agreement, together with documentation evidencing that Indemnitee has incurred such Indemnifiable Expenses.

 

4

 

10.    Indemnification for Expenses of a Witness. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness in any Proceeding to which Indemnitee is not a party, he or she shall be indemnified to the fullest extent permissible by applicable law against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.

 

11.    Remedies of Indemnitee.

 

(a)    Right to Petition Court. In the event that Indemnitee makes a request for payment of Indemnifiable Amounts under Sections 3 and 5 above or a request for an advancement of Indemnifiable Expenses under Sections 8 and 9 above and the Company fails to make such payment or advancement in a timely manner pursuant to the terms of this Agreement, Indemnitee may petition the Court of Chancery of the State of Delaware to enforce the Company’s obligations under this Agreement.

 

(b)    Burden of Proof. In any judicial proceeding brought under Section 11(a) above, the Company shall have the burden of proving that Indemnitee is not entitled to payment of Indemnifiable Amounts hereunder.

 

(c)    Expenses. The Company agrees to reimburse Indemnitee in full for any Expenses in connection with any Proceeding incurred by Indemnitee in connection with investigating, preparing for, litigating, defending or settling any action brought by Indemnitee under Section 11(a) above, or in connection with any claim or counterclaim brought by the Company in connection therewith, whether or not Indemnitee is successful in whole or in part in connection with any such action, except to the extent that it has been finally adjudicated by a court of competent jurisdiction that such reimbursement would be unlawful.

 

(d)    Failure to Act Not a Defense. The failure of the Company (including its Board of Directors or any committee thereof, independent legal counsel or stockholders) to make a determination concerning the permissibility of the payment of Indemnifiable Amounts or the advancement of Indemnifiable Expenses under this Agreement shall not be a defense in any action brought under Section 11(a) above, and shall not create a presumption that such payment or advancement is not permissible.

 

12.    Defense of the Underlying Proceeding.

 

(a)    Notice by Indemnitee. Indemnitee agrees to notify the Company promptly upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding which may result in the payment of Indemnifiable Amounts or the advancement of Indemnifiable Expenses hereunder; provided, however, that the failure to give any such notice shall not disqualify Indemnitee from the right, or otherwise affect in any manner any right of Indemnitee, to receive payments of Indemnifiable Amounts or advancements of Indemnifiable Expenses unless the Company’s ability to defend in such Proceeding is materially and adversely prejudiced thereby.

 

5

 

(b)    Defense by Company. Subject to the provisions of the last sentence of this Section 12(b) and of Section 12(c) below, the Company shall have the right to defend Indemnitee in any Proceeding which may give rise to the payment of Indemnifiable Amounts hereunder; provided, however, that the Company shall notify Indemnitee of any such decision to defend within ten (10) calendar days of the Company’s receipt of notice of any such Proceeding under Section 12(a) above. The Company shall not, without the prior written consent of Indemnitee, consent to the entry of any judgment against Indemnitee or enter into any settlement or compromise which (i) includes an admission of fault of Indemnitee or (ii) does not include, as an unconditional term thereof, the full release of Indemnitee from all liability in respect of such Proceeding, which release shall be in form and substance reasonably satisfactory to Indemnitee. This Section 12(b) shall not apply to a Proceeding brought by Indemnitee under Section 11(a) above or pursuant to Section 20 below.

 

(c)    Indemnitees Right to Counsel. Notwithstanding the provisions of Section 12(b) above, in any Proceeding to which Indemnitee is a party by reason of Indemnitee’s Corporate Status, at the Indemnittee’s option Indemnitee shall have the right to retain counsel of Indemnitee’s choice, at the expense of the Company, to represent Indemnitee in connection with any such matter and the Expenses incurred by Indemnitee in any such matter shall constitute Indemnifiable Expenses.

 

13.    Representations and Warranties of the Company. The Company hereby represents and warrants to Indemnitee as follows:

 

(a)    Authority. The Company has all necessary power and authority to enter into, and be bound by the terms of, this Agreement, and the execution, delivery and performance of the undertakings contemplated by this Agreement have been duly authorized by the Company.

 

(b)    Enforceability. This Agreement, when executed and delivered by the Company in accordance with the provisions hereof, shall be a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, moratorium, reorganization or similar laws affecting the enforcement of creditors’ rights generally.

 

14.    Insurance. The Company shall, from time to time, make the good faith determination whether or not it is practicable for the Company to obtain and maintain a policy or policies of insurance with a reputable insurance company providing the Indemnitee with coverage for losses from wrongful acts. For so long as Indemnitee shall have Corporate Status, Indemnitee shall be named as an insured in all policies of director and officer liability insurance in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s officers and directors. If, at the time of the receipt of a notice of a claim pursuant to the terms of this Agreement, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. Notwithstanding the foregoing, the Company shall have no obligation to obtain or maintain such insurance if the Company determines in good faith that such insurance is not reasonably available, if the premium costs for such insurance are disproportionate to the amount of coverage provided, or if the coverage provided by such insurance is limited by exclusions so as to provide an insufficient benefit.

 

6

 

15.    No Duplication of Payments. The Company shall not be liable under this Agreement to make any payment in connection with any claim made against Indemnitee to the extent Indemnitee has otherwise actually received payment under any insurance policy, provision of the Certificate or the Bylaws or otherwise of the amounts otherwise indemnifiable hereunder. The Company’s obligation to indemnify or advance Expenses hereunder to Indemnitee as a result of the Indemnitee’s Corporate Status with an Entity other than the Company shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other Entity.

 

16.    Contract Rights Not Exclusive. The rights to payment of Indemnifiable Amounts and advancement of Indemnifiable Expenses provided by this Agreement shall be in addition to, but not exclusive of, any other rights which Indemnitee may have at any time under applicable law, the Certificate or Bylaws, or any other agreement, vote of stockholders or directors (or a committee of directors) or otherwise, both as to action in Indemnitee’s official capacity and as to action in any other capacity as a result of Indemnitee’s serving as a director of the Company.

 

17.    Successors. This Agreement shall be (a) binding upon all successors and assigns of the Company (including any transferee of all or a substantial portion of the business, stock and/or assets of the Company and any direct or indirect successor by merger or consolidation or otherwise by operation of law) and (b) binding on and shall inure to the benefit of the heirs, personal representatives, executors and administrators of Indemnitee. This Agreement shall continue for the benefit of Indemnitee and such heirs, personal representatives, executors and administrators after Indemnitee has ceased to have Corporate Status.

 

18.    Change in Law. To the extent that a change in Delaware law (whether by statute or judicial decision) or the Certificate shall permit broader indemnification or advancement of expenses than is provided under the terms of the Bylaws and this Agreement, Indemnitee shall be entitled to such broader indemnification and advancements, and this Agreement shall be deemed to be amended to such extent.

 

19.    Severability. Whenever possible, each provision of this Agreement shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Agreement, or any clause thereof, shall be determined by a court of competent jurisdiction to be illegal, invalid or unenforceable, in whole or in part, such provision or clause shall be limited or modified in its application to the minimum extent necessary to make such provision or clause valid, legal and enforceable, and the remaining provisions and clauses of this Agreement shall remain fully enforceable and binding on the parties.

 

20.    Indemnitee as Plaintiff. Except as provided in Section 11(c) of this Agreement and in the next sentence, Indemnitee shall not be entitled to payment of Indemnifiable Amounts or advancement of Indemnifiable Expenses with respect to any Proceeding brought by Indemnitee against the Company, any Subsidiary, any Entity which it controls, any director or officer thereof or any third party, unless the Board of Directors has consented to the initiation of such Proceeding or the Company provides indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law. This Section shall not apply to counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee.

 

7

 

21.    Modifications and Waivers; Counterparts. Except as provided in Section 18 above with respect to changes in Delaware law which broaden the right of Indemnitee to be indemnified by the Company or to receive advancements, no supplement, modification or amendment of this Agreement shall be binding unless executed in writing by each of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement (whether or not similar), nor shall such waiver constitute a continuing waiver. This Agreement may also be executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same Agreement.

 

22.    General Notices. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given (a) when delivered by hand, (b) when transmitted by facsimile and receipt is acknowledged during normal business hours, and if not, the next business day after transmission or (c) if mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:

 

 

(i)

If to Indemnitee, to:

 

 

 

 

(ii)

If to the Company, to:

 

CervoMed Inc.

20 Park Plaza, Suite 424

Boston, MA 02116

Attn: Chief Executive Officer

 

 

or to such other address as may have been furnished in the same manner by any party to the others.

 

8

 

23.    Governing Law; Consent to Jurisdiction; Service of Process. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without regard to its rules of conflict of laws. Each of the Company and Indemnitee hereby irrevocably and unconditionally consents to submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware and the courts of the United States of America located in the State of Delaware (the “Delaware Courts”) for any litigation arising out of or relating to this Agreement and the transactions contemplated hereby (and agrees not to commence any litigation relating thereto except in such courts), waives any objection to the laying of venue of any such litigation in the Delaware Courts and agrees not to plead or claim in any Delaware Court that such litigation brought therein has been brought in an inconvenient forum. Each of the parties hereto agrees, (a) to the extent such party is not otherwise subject to service of process in the State of Delaware, to appoint and maintain an agent in the State of Delaware as such party's agent for acceptance of legal process, and (b) that service of process may also be made on such party by prepaid certified mail with a proof of mailing receipt validated by the United States Postal Service constituting evidence of valid service. Service made pursuant to (a) or (b) above shall have the same legal force and effect as if served upon such party personally within the State of Delaware. For purposes of implementing the parties’ agreement to appoint and maintain an agent for service of process in the State of Delaware, each such party does hereby appoint The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, as such agent and each such party hereby agrees to complete all actions necessary for such appointment.

 

24.    Joinders. Subsidiaries of the Company may from time to time join this Agreement by signing a joinder in substantially the form attached hereto as Exhibit A. The Company and all Subsidiaries that have joined this Agreement shall be jointly and severally liable for all obligations of the Company under this Agreement.

 

25.    Assignment. Except as otherwise set forth herein, neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned by any party hereto, without the prior written consent of all of the other parties hereto.

 

26.    Entire Agreement. Without limitation to the Certificate and the Bylaws, this Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.

 

[The remainder of this page is intentionally blank]

 

9

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement as of the day and year first above written.

 

 

CERVOMED INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ 

 

 

 

Name:

 

 

 

Title:

 

 

 

 

INDEMNITEE

 

 

 

 

 

 

 

 

 

 

By:

/s/ 

 

 

 

Name:

 

 

 

Title:

 

 

[Signature Page to Fund Indemnification Agreement]


 

EXHIBIT A

 

JOINDERS

 

The undersigned hereby join in the obligations of CervoMed Inc. under this Indemnification Agreement as provided in Section 24 above on this ___ day of ____________, 20[__].

 

 

[         ]

 

 

 

 

 

 

 

 

 

 

By:

/s/ 

 

 

 

Name:

 

 

 

Title:

 

 

 

 

[         ]

 

 

 

 

 

 

 

 

 

 

By:

/s/ 

 

 

 

Name:

 

 

 

Title:

 

 

 

[Signature Page to Joinder to Indemnification Agreement]

EX-16.1 10 ex_562005.htm EXHIBIT 16.1 ex_562005.htm

Exhibit 16.1

 

August 17, 2023

 

Securities and Exchange Commission
Washington, D.C. 20549

 

Ladies and Gentlemen:

 

We were previously principal accountants for CervoMed Inc., formerly known as Diffusion Pharmaceuticals Inc., (the Company) and, under the date of March 24, 2023, we reported on the consolidated financial statements of Diffusion Pharmaceuticals Inc. as of and for the years ended December 31, 2022 and 2021. On August 16, 2023, we were dismissed.

 

We have read the Company’s statements included under Item 4.01 of its Form 8-K dated August 15, 2023, and we agree with such statements except we are not in a position to agree or disagree with the Company’s statement that the dismissal of KPMG LLP was approved by the Audit Committee of the board of directors, and we are not in a position to agree or disagree with the Company‘s statements in Item 4.01(b).

 

 

Very truly yours,

 

/s/ KPMG LLP

 

 
EX-99.1 11 ex_562006.htm EXHIBIT 99.1 ex_562006.htm

Exhibit 99.1

 

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

 

Approximately 71% of Stockholders Voted in Favor of the Transaction

Diffusion Announces 1-for-1.5 Reverse Stock Split

Merger on Track to Close on August 16, 2023

 

 

CHARLOTTESVILLE, VA, August 15, 2023 – Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) today announced that its stockholders have voted to approve all proposals at a special meeting of stockholders held earlier today, including the issuance of Diffusion Common Stock in the pending merger with EIP Pharma Inc. (“EIP”), and a reverse stock split of outstanding Diffusion Common Stock (the “Reverse Split”).

 

Dr. Robert Cobuzzi, President and Chief Executive Officer of Diffusion, said, “We are pleased with the outcome of today’s special meeting and thank our stockholders for their support of the merger with EIP. The fact that stockholders holding more than 71% of the votes cast voted in favor of the transaction, and 73% of the votes cast voted in favor of the Reverse Split provides further confidence that our thorough strategic process maximizes value for stockholders.”

 

“We look forward to completing the merger and realizing our bright future as CervoMed. Looking ahead, we believe our stockholders are positioned to benefit from the upside potential of ownership in the combined company, where the team will be building on the great work the EIP team has done in developing neflamapimod, including yesterday’s announcement that the first patient has been dosed in the RewinD-LB Phase 2b clinical trial of the company’s lead asset, neflamapimod, for the treatment of patients with dementia with Lewy bodies (DLB).”

 

In connection with the special meeting, Diffusion’s board of directors met and voted to implement the lowest Reverse Split ratio, 1-for-1.5, to maintain compliance with the $4 per share minimum bid price requirement for an initial listing on any Nasdaq market tier. As such, pending completion of the merger, the combined company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on August 17, 2023, under the new trading symbol “CRVO.” As a result of the reverse stock split and the merger, the CUSIP number for Diffusion’s common stock will now be 15713L109.

 

The merger is expected to close after the close of business close on August 16, 2023, subject to customary closing conditions. The final voting results for the company’s special meeting will be disclosed in a Form 8-K filed with the Securities and Exchange Commission (the “SEC”) and will also be available at https:// https://investors.diffusionpharma.com/sec-filings/, after certification by the company’s inspector of elections.

 

Canaccord Genuity is serving as financial advisor to Diffusion, and Dechert LLP is serving as legal counsel to Diffusion.

 

 

 

About Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. is a biopharmaceutical company that has historically focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most. Diffusion’s most advanced product candidate, trans sodium crocetinate (TSC), has been investigated and developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, most recently as an adjuvant treatment to standard of care therapy for GBM and other hypoxic solid tumors. In connection with the proposed merger with EIP, and pending its conclusion, Diffusion previously paused the initiation of the previously announced Phase 2 study of TSC in newly diagnosed GBM patients and will continue to attempt to identify sale or out-licensing transactions.

 

For more information, please visit www.diffusionpharma.com or engage with us on Twitter and LinkedIn.

 

Forward-Looking Statements

This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including, but not limited to, the timing and potential outcome of the proposed transaction between Diffusion Pharmaceuticals and EIP Pharma; the therapeutic potential of neflamapimod; anticipated milestones related to the development of the combined company’s clinical programs and reporting of data; the expected ownership percentages of the combined company; and the expected management team and board of directors of the combined company. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey uncertainty of future events or outcomes may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the parties’ control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to the timing and completion of the proposed transaction, including the satisfaction of closing conditions; the cash balances of the combined company following the closing, if completed, of the proposed transaction; the ability of Diffusion Pharmaceuticals to remain listed on the Nasdaq Capital Market, as well as comply with any Nasdaq rules and regulations related to the proposed transaction; the price of Diffusion Pharmaceuticals’ securities, which may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Diffusion Pharmaceuticals and/or EIP Pharma operates; variations in operating performance across competitors; changes in laws and regulations affecting Diffusion Pharmaceuticals’ or EIP Pharma’s business; the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in Diffusion Pharmaceuticals’ most recent Annual Report on Form 10-K, the proxy statement/prospectus/information statement included in the Registration Statement on Amendment No. 2 to Form S-4, File No. 333-271823, filed by the Company with the SEC on July 12, 2023 and declared effective by the SEC on July 13, 2023, and other filings with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These risks, as well as other risks associated with the merger, will be more fully discussed in the proxy statement/prospectus that will be included in the registration statement that will be filed with the SEC in connection with the proposed transaction and, except as required by applicable law, rule, or regulation, neither Diffusion Pharmaceuticals nor EIP Pharma undertakes any obligation to update any such statements after the date hereof.

 

Contacts

Diffusion Investors: 
Tiberend Strategic Advisors, Inc.  
Daniel Kontoh-Boateng 
dboateng@tiberend.com

 

EIP Investors & Media: 
Argot Partners 
212.600.1902 
EIP@argotpartners.com

 

 

 
EX-99.2 12 ex_562007.htm EXHIBIT 99.2 ex_562007.htm

Exhibit 99.2

 

cervologo.jpg

 

CervoMed Announces Completion of Merger with EIP Pharma

 

Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023

 

CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with Lewy bodies and other degenerative diseases of the brain

 

CervoMed has a cash runway through Phase 2b clinical data which is expected during 2H 2024

 

BOSTON, MA August 16, 2023 – CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced the closing of its previously announced merger with EIP Pharma Inc. The combined company will operate under the name CervoMed Inc., and its shares will commence trading on a 1-for-1.5 reverse split adjusted basis on August 17, 2023, on the Nasdaq Capital Market under the ticker symbol “CRVO”. CervoMed’s focus will be on advancing its lead drug candidate neflamapimod, an oral stress kinase inhibitor, which is currently being developed for the treatment of dementia with Lewy bodies (DLB) and other degenerative diseases of the brain.

 

“This merger with Diffusion, launch of CervoMed and entry into the public market is a transformative event that will accelerate the advancement of neflamapimod, first, and over the coming year, for the treatment of DLB, and later in Alzheimer’s disease and stroke recovery,” said John Alam, MD, Chief Executive Officer of CervoMed. “We are excited about the potential for neflamapimod to be the first-to-market disease-modifying drug therapy for DLB, with the potential to reverse and slow the progression of synaptic dysfunction that contributes to the typical cognitive and motor function decline associated with this devastating disease. Now that our Phase 2b DLB study, named RewinD-LB is underway, we anticipate completing enrollment during the first half of next year and reporting data from the placebo-controlled portion of the study during the second half of next year. We are well-funded through these catalysts and believe we are well-positioned to achieve our goal of creating new medicines for the brain.”

 

“I am pleased by the close of this merger and the value I believe it will bring to Diffusion shareholders thanks to CervoMed’s encouraging CNS pipeline. I would particularly like to thank our executive team and board of directors for their significant efforts throughout the process leading to the closing of this merger,” said Robert J. Cobuzzi, Jr., Ph.D., former Chief Executive Officer of Diffusion Pharmaceuticals and Chief Operating Officer of CervoMed. “I look forward to the opportunity to serve CervoMed in my new role as COO, contributing to the Company’s efforts in our mission of bringing new medicines to patients living with degenerative diseases of the brain.”

 

Upcoming Anticipated Catalysts/Milestones

 

The Company has several anticipated catalysts and development milestones for neflamapimod through the end of 2024, including:

 

 

Publication of additional results from the Phase 2a clinical study in DLB in a peer-reviewed medical journal in the second half of 2023

 

 

 

cervologo.jpg

 

 

Oral presentation of the RewinD-LB Phase 2b clinical study design at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in October 2023

 

 

Completion of enrollment into the RewinD-LB Phase 2b clinical study in DLB in the first half of 2024

 

 

Reporting of data from placebo-controlled portion of RewinD-LB during the second half of 2024

 

As announced on August 14, 2023, by EIP Pharma, following first-patient dosing, the RewinD-LB study is a randomized, 16-week double-blind, placebo-controlled phase 2b clinical trial of oral 40mg neflamapimod, three-times-per-day, in 160 patients with prodromal DLB or mild dementia due to DLB. Patients with Alzheimer's disease-related co-pathology, assessed by a blood biomarker, will be excluded. All patients completing the placebo-controlled main study will receive an additional 32 weeks of neflamapimod on an open-label basis.

 

EIP Pharma was previously awarded a $21 million grant from the National Institutes of Health’s National Institute on Aging (NIA) which will fully fund development costs associated with the ongoing Phase 2b DLB study. The NIA grant funds will be disbursed over the course of the study as costs are incurred.

 

Transaction Details

 

In connection with the closing of the merger, Diffusion Pharmaceuticals enacted a 1-for-1.5 reverse stock split of its common stock. Following the reverse stock split and closing of the merger, there will be approximately 5.7 million shares of the combined company’s common stock outstanding, with prior EIP Pharma shareholders owning approximately 77.95% and prior Diffusion Pharmaceuticals shareholders owning 22.05%. CervoMed, Inc. will trade on the Nasdaq Capital Market under a new ticker symbol, “CRVO”.

 

The management team of EIP Pharma has become the management team of the CervoMed, led by John Alam, MD, as Chief Executive Officer and President. In addition, Robert J. Cobuzzi, Jr., PhD, the former Chief Executive Officer of Diffusion Pharmaceuticals, will serve as the Chief Operating Officer of CervoMed. The board of directors is comprised of seven directors including Dr. Alam, Sylvie Grégoire, PharmD, who will serve as Chair, Jeff Poulton, Chief Financial Officer at Alnylam, who will serve chair of the audit committee, and Diffusion Pharmaceuticals’ former Chair of the board of directors, Jane Hollingsworth, JD.

 

EIP Pharma Inc. is now a wholly owned subsidiary of CervoMed. 

 

Canaccord Genuity served as financial advisor and Dechert LLP provided legal counsel to Diffusion Pharmaceuticals. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. provided legal counsel to EIP Pharma.

 

About Neflamapimod

 

Neflamapimod is an investigational drug that is an orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). P38a, which is expressed in neurons under conditions of stress and disease, plays a major role in inflammation-induced synaptic toxicity, leading to synaptic dysfunction. Neflamapimod is currently being developed for the treatment of dementia with Lewy bodies (DLB) and is the first treatment with the potential to have a positive impact on cognition, function and motor function.

 

 

 

In preclinical studies, neflamapimod reversed synaptic dysfunction, including and particularly within the part of the brain most impacted in DLB – the basal forebrain cholinergic system. In Phase 1 and Phase 2 clinical studies involving more than 300 participants, neflamapimod has been shown to be generally well tolerated. Results from the AscenD-LB Phase 2a clinical study demonstrated that neflamapimod significantly improved dementia severity compared to placebo and also showed significant improvement on motor function compared to placebo. At the highest dose evaluated, neflamapimod improved cognition. The combined preclinical and clinical data are consistent with neflamapimod treating the underlying DLB disease process and suggest it has the potential to be the first disease-modifying treatment for DLB. Neflamapimod was granted Fast Track status by the U.S. Food and Drug Administration for the treatment of DLB and EIP Pharma was recently awarded a $21 million grant from the National Institutes of Health’s National Institute on Aging (NIA) to evaluate neflamapimod in a Phase 2b clinical study in DLB. The NIA grant funds will be disbursed over the course of study as the costs are incurred.

 

cervologo.jpg

 

About CervoMed

 

CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.

 

Forward-Looking Statements

 

This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including, but not limited to, the potential benefits of the transaction between Diffusion Pharmaceuticals and EIP Pharma; the therapeutic potential of neflamapimod; anticipated milestones related to the development of the combined company’s clinical programs and reporting of data; the expected ownership percentages of the combined company; and the expected management team and board of directors of the combined company. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or other words that convey uncertainty of future events or outcomes may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the parties’ control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related the cash balances of the combined company following the closing; the ability of the combined company to remain listed on the Nasdaq Capital Market, as well as comply with any Nasdaq rules and regulations; the price of the combined company’s securities, which may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which the combined company operates; variations in operating performance across competitors; changes in laws and regulations affecting the combined company’s business; the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, in the proxy statement/prospectus/information statement that is included in the registration statement on Form S-4 (File No. 333-271823) that was filed with the SEC, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). New factors emerge from time to time, and it is not possible for us to predict all such factors, nor can we assess the impact of each such factor on the businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.

 

Contacts

 

CervoMed Investors & Media:

Argot Partners

212.600.1902

CervoMed@argotpartners.com

 

 

 
EX-101.SCH 13 dffn-20230815.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 14 dffn-20230815_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 15 dffn-20230815_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Current Fiscal Year End Date Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, Address Line Two Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Entity, Information, Former Legal or Registered Name Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 16 dffn-20230815_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 17 cervologo.jpg begin 644 cervologo.jpg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end XML 18 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Aug. 15, 2023
Document Information [Line Items]  
Entity, Registrant Name CervoMed Inc.
Current Fiscal Year End Date --12-31
Document, Type 8-K
Document, Period End Date Aug. 15, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-24477
Entity, Tax Identification Number 30-0645032
Entity, Address, Address Line One 20 Park Plaza
Entity, Address, Address Line Two Suite 424
Entity, Address, City or Town Boston
Entity, Address, State or Province MA
Entity, Address, Postal Zip Code 02216
City Area Code 617
Local Phone Number 744-4400
Entity, Information, Former Legal or Registered Name Diffusion Pharmaceuticals Inc.
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CRVO
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001053691
XML 19 dffn20230816_8k_htm.xml IDEA: XBRL DOCUMENT 0001053691 2023-08-15 2023-08-15 false 0001053691 --12-31 8-K 2023-08-15 CervoMed Inc. DE 001-24477 30-0645032 20 Park Plaza Suite 424 Boston MA 02216 617 744-4400 Diffusion Pharmaceuticals Inc. false false false false Common Stock CRVO NASDAQ false EXCEL 20 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /R!$5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #\@1%7IYMC;>\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)OIW^H2NCFHGA2$%Q0O(7)[&ZP:4,RTN[;V\;=+J(/X#$SOWSS M#4R+7N(0Z#D,G@);BE>3Z_HHT6_$@=E+@(@'X*J**[!$6NC6<,"S/Q*%*HU*#&0YB&<\ 97O/\,78(9!.K(4<\1RKP$H9:) M_CAU+5P "XPIN/A=(+,24_5/;.J ."6G:-?4.([Y6*?&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #\@1%70M#X/I\$ "/$@ & 'AL+W=OO,KERM@'[=%@S9=B)LQO:U_#7;M4"64BTDRJE&@1#9TQO;EE M?=N@J/%5BDUV5":V*PNEWNS--!PZKB42L0B,E>!P>1<3$<=6"3C^WHLZY3=M MP^/R0?VAZ#QT9L$S,5'Q-QF:U="YP; T$BT]V5?^P'XJA!AYYHP/8-6,&]^U!!><<-'PVTVA!M:X.: M+11=+5H#G$SMK,R,AK<2VIG1G0IR&&1#QFE([E,CS99,T]ULPZ@-V@8^8JNV M@[W@[4Z0G1 ).TJN7M(%^DZUY((8.1'(F]+MP1M]_1WON3PAPIP3N8.JCW2!>D%>QE)G1 M'-"?>2+J,'&A"8"I)Q%"SX-+!,PKP3Q<+]?:#N2#S (>D]\%US#C(8&XJ:7# MU5HMREH=BG!U2ZXNJG28X0LRWZYK2?#V5ZTO"$6OI.B=2>$++56(#@TN52Z! MIC70+]GZ9X44!(+2:Z6+17!!9@;PB-)DHO+4Z"U+ADQVVY M/:_K=AC"1]W*>=VS",=A""Z4E052F-M+6CN5#9K,)3[7;\2/^3\R"YR(-8:)?HJ@^$AOT&LFJO,!P M#_]$-LVR',@: 7'91L"C_PVXC<^E@:V(B@AE/RQ^)#,1Y!!OVUHF7,G&)ZR# MF5'!&X96I06&._A<\]"&V&R;+%1M@#4(3%Z_OF D51)@N&,?1H7S^[&OV),E?EB$^T/,E[4HN$ C2I4'V'EY8 (T&EQ_"NON@WP1]0.$:[FP\W:[G=YU M[?^Y]M'Q@CVJ>>)V7C(2BPC4W,L^C+[>G7[L;HQ:%R<."V6,2HKB2G"P!5L! MWD=*F<.-/<0HSZ!&_P)02P,$% @ _($15Y^@&_"Q @ X@P T !X M;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ M9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD M:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N M0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!I MGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87 M$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%> M* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK'O;^ MRPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/- M-;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'-M[#/ M)73)>UYN1]76^T$D7O!9QP<&%Y_J?]K-#] M! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q M P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL M0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ _($15Y>*NQS M $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/ M:(7->=I3W;+T]!;X"O M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_ M'36TGHX-R#8._AE8P=S8\?=_<#4$L#!!0 M ( /R!$5&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&R MGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0 MDBBZ0=@S9)[NF:*'3^ 5!+ M P04 " #\@1%799!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX M;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85- MK'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+ MY8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE# MVQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/) MW55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_ ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( /R!$5<'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ _($1 M5Z>;8VWO *P( !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ _($15YE&PO=V]R:W-H965T&UL4$L! A0#% @ _($15Y^@&_"Q @ X@P T ( ! MXPP 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL M4$L! A0#% @ _($15R0>FZ*M ^ $ !H ( !%1( M 'AL+U]R96QS+W=O9(9 0 SP, !, ( !^A( %M#;VYT96YT7U1Y<&5S72YX 8;6Q02P4& D "0 ^ @ 1!0 end XML 21 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 22 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 23 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 25 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.dffn.com/20230815/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports dffn20230816_8k.htm dffn-20230815.xsd dffn-20230815_def.xml dffn-20230815_lab.xml dffn-20230815_pre.xml ex_561997.htm ex_561998.htm ex_561999.htm ex_562000.htm ex_562001.htm ex_562002.htm ex_562003.htm ex_562004.htm ex_562005.htm ex_562006.htm ex_562007.htm http://xbrl.sec.gov/dei/2023 true false JSON 25 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dffn20230816_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "dffn-20230815_def.xml" ] }, "inline": { "local": [ "dffn20230816_8k.htm" ] }, "labelLink": { "local": [ "dffn-20230815_lab.xml" ] }, "presentationLink": { "local": [ "dffn-20230815_pre.xml" ] }, "schema": { "local": [ "dffn-20230815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 25, "memberCustom": 0, "memberStandard": 0, "nsprefix": "dffn", "nsuri": "http://www.dffn.com/20230815", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dffn20230816_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.dffn.com/20230815/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "dffn20230816_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity, Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity, Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.dffn.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 26 0001437749-23-024064-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-024064-xbrl.zip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end